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1 
SUMMARY 
 
Leukemias are the most common form of pediatric cancers, and whereas Acute Lymphoblastic 
Leukemia (ALL) treatment has made significant progresses over the past decades reaching up to 86% 
of survival, Acute Myeloid Leukemia (AML) survival rate reaches the 60%, and 30% of those patients 
relapsed within 1/2 years from remission. The cyclic adenosine monophosphate (cAMP) responsive 
element binding protein (CREB) has been found to be overexpressed in the leukemic blast cells of 
66% of patients with AML and in the 84% of patients with ALL, compared to normal bone marrow or 
remission samples. CREB overexpression in AML patients was also correlated with a worse prognosis 
and increased risk of relapse. Nevertheless, CREB’s role in AML pathogenesis is still debated. In this 
work I identified three main ways in order to target CREB overexpression: ICER, its endogenous 
repressor; the miR-34b which targets its 3’UTR; the zebrafish as an in vivo model where new 
molecules can be tested. 
CREB level has been shown to be controlled by the inducible cAMP early repressor (ICER), 
an endogenous CREB competitor able to recognize cAMP responsive element (CRE) sequences and 
stop transcriptional activity. ICER level was found downregulated in AML, failing to control CREB 
transcriptional activity, thus sustaining leukemia. Restoration of ICER expression in leukemic cell 
lines and in AML primary cultures, led to a decreased expression of CREB and its target genes. 
Among the genes affected by ICER restoration, impairment of the dual-specificity phosphatases 
DUSP1 and DUSP4 was found. The decreased level of DUSPs1/4 directly sustained the p38-mediated 
apoptotic pathway, which in turn triggered caspase-dependent apoptosis. This important ICER role in 
cell death, led us to focus the attention on combining its action together with specific drug treatment. 
AML cell lines reduced cell growth and enhanced apoptotic behavior after chemotherapy treatment if 
ICER was expressed. A significant lowered expression of CREB target genes involved in cell cycle 
control (CyA1, B1, D1), and in mitogen-activated protein kinase signaling pathway (ERK, AKT, 
DUSP1/4) was found after Etoposide (a topoisomerase inhibitor used in therapy of AML) treatment. 
To verify the involvement of DUSPs on p38 activation, we silenced DUSPs1/4 in HL60 cell lines, and 
we confirmed the same enhanced drug sensitivity induced by ICER. Moreover, DUSPs1/4 silencing or 
ICER restoration in primary AML cultures showed DUSP1 downregulation and p38 activation. ICER 
has been demonstrated to mediate chemotherapy activity by DUSP1-p38 pathway activation, thus 
reprogramming leukemic cells from survival to apoptosis. These results supported important effects of 
ICER restoration which mediated CREB activity, remarking the involvement of CREB in sustaining 
leukemia.  
Thus we argued to seek out the cause of CREB overexpression in AML, and giving that it was 
found overexpressed in its proteic form, we looked at translational control, focusing on microRNAs. 
We found that miR-34b targeted the 3’UTR of CREB gene, and was downregulated in AML. We 
dissected its role in inducing CREB overexpression. We used AML cell lines and revealed the 
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hypermethylation of its promoter. Thus, we analyzed miR-34b expression and methylation status of its 
promoter in cells from patients diagnosed with myeloid malignancies. We found that miR-34b was 
upregulated, since it was not hypermethylated at its promoter, in pediatric patients affected by 
preleukemic hematopoietic disease as juvenile myelomonocytic leukemia (JMML, n=17) and 
myelodysplastic syndrome (MDS n=28) with the concomitant low CREB expression. On the other 
hand, miR-34b was downregulated in AML patients at diagnosis (n=112). Our results showed that 
hypermethylation of the miR-34b promoter occurred in 66% of acute myeloid leukemia, explaining 
the low miR-34b levels and CREB overexpression, whereas preleukemic MDS and JMML patients 
were not associated with hypermethylation nor CREB overexpression. Interestingly, in paired samples 
of MDS evolved into AML, we confirmed miR-34b promoter hypermethylation at leukemia onset, and 
gene expression profile revealed 103 CREB target genes differentially expressed between the two 
disease stages. This subset of CREB targets was confirmed to associate with high risk MDS in a 
separate cohort of patients (n=20), identifying a signature of myeloid transformation To confirm this 
hypothesis, we evaluated miR-34b tumor suppressor potential in vitro and in vivo, finding that miR-
34b restoration decreased AML engraftment and progression through CREB-dependent pathways. 
These results confirmed that miR-34b controlled CREB expression and contributed to myeloid 
transformation. Furthermore, we identified a subset of CREB target genes that represents a novel 
transcriptional network involved in tumor formation, and their functional activity may be further 
pursued. 
We considered to test CREB and its target genes’ role in mediating MDS and AML in a 
suitable in vivo model, such as zebrafish. We chose this model organism for its numerous advantages 
that led to its widespread use in both developmental studies and cancer research, such as high 
regenerative ability, rapid and transparent embryonic development, and easy genetic manipulation. We 
integrated a plasmid coding human CREB under pu.1 promoter into fertilized egg at one cell stage to 
overexpress CREB in the myeloid lineage. Results showed that CREB-overexpression led to 
hematopoiesis perturbation in embryos at 24 and 48 hours post fertilization, with an altered CREB 
target gene expression, that conferred an enhanced cell cycle progression. Since 6 months after CREB 
enforced expression, zebrafish kidney marrow showed dysmyelopoiesis, with increased monocytes 
and myelocytes rates. At the age of 9 months, CREB-overexpressing zebrafish developed a sick 
phenotype with abdominal and dorsal enlargement that at morphological evaluation resembled an 
abdominal mass formed by clonal cells with infiltrating capability. The mass cells were found to 
originate from the cells overexpressing human CREB, to rapidly proliferate and to migrate into gills, 
adipose tissue and muscles. Mass cell morphology was similar to that of kidney marrow with a 
complete lack of myelocytes, and a preponderance of monocytes, confirming a myeloproliferative 
disease. These results demonstrated that zebrafish overexpressing CREB resembled the same 
dysmyelopoiesis already seen in vitro and in CREB transgenic mice, with a relevant perturbed CREB 
target gene expression. The long latency of disease onset suggested that additional events may occur.  
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Neverthless, CREB-overexpressing zebrafish model recapitulated a CREB-mediated 
myeloproliferative disease: it represents a useful model with high potentialities in dissecting CREB 
role on malignant transformation. Moreover, the use of ICER and miR-34b as tumor suppressors, as 
well as the screen of novel compounds which may be confidently tested, will open for further 
therapeutic opportunities. 
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SOMMARIO 
 
La leucemia è il cancro più diffuso nell’età pediatrica. Oggigiorno, le cure per la Leucemia 
Linfoide Acuta (LAL) hanno portato a progressi molto significativi, con una sopravvivenza dei 
pazienti che raggiunge l’86%, mentre il trattamento contro la Leucemia Mieloide Acuta (LAM) ha 
raggiunto una quota di sopravvivenza del 60%, ma entro 1/2 anni dalla remissione il 30% di questi 
ultimi ricade. Uno dei principali scopi della ricerca nelle LAM è quello di identificare nuovi marcatori 
molecolari che siano in grado di identificare geneticamente alcuni sottogruppi di LAM, e anche di 
comprendere la leucemogenesi. A questo scopo, negli ultimi anni è stato identificato il gene CREB 
(cyclic adenosine monophosphate (cAMP) responsive element binding protein), che codifica per un 
fattore di trascrizione implicato nelle principali attività cellulari. Nel 66% dei pazienti affetti da LAM, 
e nell’84% dei pazienti affetti da LAL, è stata trovata una sovra espressione della proteina CREB 
rispetto alla espressione fisiologica dello stesso riscontrata in cellule di midollo osseo di donatori sani 
o di pazienti in remissione. Inoltre è stata trovata una correlazione tra la sovra espressione di CREB 
nelle LAM, ed una prognosi peggiore con un aumentato rischio di ricaduta. Ciononostante, il ruolo di 
CREB nella patogenesi delle LAM rimane ancora dibattuto. In questo lavoro, ho utilizzato tre diverse 
strade per agire sulla sovra espressione di CREB: ICER, il suo repressore endogeno; miR-34b, 
microRNA che si lega alla sua regione 3’UTR; lo zebrafish, come modello in vivo per poter testare 
nuove molecole.  
In lavori precedenti è stato dimostrato che l’espressione di CREB è controllata dalla presenza 
di ICER (inducible cAMP early repressor), un inibitore endogeno di CREB. ICER infatti compete con 
CREB per legare le sequenza responsive CRE che si trovano nel promotore dei geni target, e blocca 
l’attività trascrizionale. Il livello di ICER è stato trovato sotto espresso nelle LAM, con una 
conseguente perdita di inibizione sull’attività trascrizionale di CREB, promuovendo così l’avanzare 
della leucemia. In questo lavoro siamo andati a studiare il ruolo di ICER introducendolo in forma 
esogena nelle linee cellulari leucemiche e nelle culture primarie di LAM. La riespressione di ICER 
portava ad una diminuzione dell’espressione di CREB e dei suoi geni target. Tra questi ultimi, in 
particolare, era stata trovata una diminuzione dell’espressione di DUSP1 e DUSP4 (dual-specificity 
phosphatases). Abbiamo verificato che la riduzione delle DUSPs1/4 andava ad attivare direttamente 
p38, che a sua volta induceva l’apoptosi caspasi-dipendente. Dato il coinvolgimento di ICER nella 
morte cellulare, abbiamo cercato di combinare la sua azione al trattamento farmacologico 
chemioterapico. Nel trattamento delle linee cellulari leucemiche, questa combinazione ha portato ad 
una riduzione della crescita cellulare e ad un aumento dell’apoptosi. In seguito al trattamento con 
Etoposide (un inibitore delle topoisomerasi usato nella terapia delle LAM), si riscontrava una 
diminuzione significativa dell’espressione dei geni target di CREB coinvolti nel ciclo cellulare (CyA1, 
B1,D1), e nei geni cha fanno parte della via di segnale MAPK (ERK, AKT, DUSP1/4). Per verificare 
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che l’attivazione di p38 fosse realmente indotta dall’abbassamento delle DUSPs, abbiamo silenziato 
DUSPs1/4 nella linea cellulare leucemica HL60, confermando lo stesso aumento di sensibilità al 
trattamento chemioterapico provocata dalla reintroduzione di ICER. Inoltre, il silenziamento delle 
DUSPs1/4 o l’espressione esogena di ICER nelle culture primarie di LAM, portavano 
all’abbassamento di DUSP1 e all’attivazione di p38. In questo lavoro abbiamo dimostrato che ICER 
aiuta l’attività chemioterapica attraverso l’attivazione della via di segnale DUSP-p38, riprogrammando 
quindi le cellule leucemiche dalla sopravvivenza all’apoptosi. Questi risultati suggeriscono che ICER 
ha un importante ruolo di regolatore di CREB.  
Ci siamo poi interessati a scoprire la causa della sovra espressione di CREB nelle LAM. Dato 
che CREB risulta sovra espresso in forma proteica, siamo andati a valutare la sua regolazione 
traslazionale, focalizzandoci sui microRNA. E’ stato dimostrato che uno di questi, il miR-34b, si lega 
alla la regione 3’UTR del gene CREB, ed è sotto espresso nelle LAM. Con studi in vitro su linee 
cellulari di LAM, abbiamo scoperto che la down regolazione del miR-34b era dovuta 
all’ipermetilazione del suo promotore. Quindi siamo andati a valutare la funzione del miR-34b come 
modulatore di CREB. analizzando la sua espressione e la metilazione del suo promotore nei pazienti 
affetti da patologie mieloidi. Nei pazienti pediatrici affetti da disordini ematopoietici preleucemici, 
come la JMML (juvenile myelomonocytic leucemia, n=17) e MDS (myelodysplastic sindrome, n=28) 
abbiamo trovato una normale espressione di miR-34b, unitamente ad una bassa espressione di CREB. 
Al contrario, nei pazienti alla diagnosi di LAM (n=112), il miR-34b è stato trovato sotto espresso. Nel 
66% delle LAM, è stata riscontrata l’ipermetilazione del suo promotore, spiegando così la bassa 
espressione di miR-34b e la sovra espressione di CREB, mentre nei pazienti affetti da malattie 
preleucemiche come JMML e MDS, non è stata trovata la metilazione del promotore di miR-34b, e 
l’espressione di CREB è risultata infatti normale.  
Dall’analisi di alcuni pazienti affetti da MDS e successivamente evoluti in LAM, abbiamo 
confermato che l’ipermetilazione del promotore di miR-34b insorgeva al momento dell’evoluzione in 
LAM. Inoltre, tracciando un profilo di espressione genica dei suddetti pazienti, abbiamo scoperto che 
103 geni target di CREB erano differenzialmente espressi tra le due fasi di malattia. In una coorte 
separata di pazienti (n=20) è stato confermato che lo stesso sottogruppo di geni target di CREB era 
associato ad MDS ad alto rischio di evoluzione in LAM, identificando così uno specifico profilo di 
trasformazione leucemica. Per verificare ulteriormente la nostra ipotesi, abbiamo valutato il miR-34b 
come potenziale oncosoppressore in vitro e in vivo, trovando che la sua espressione esogena portava 
alla diminuzione sia della progressione tumorale che dell’invasione dei tessuti, inibendo l’azione di 
CREB e l’espressione dei suoi geni target. Questi risultati hanno confermato che il miR-34b controlla 
l’espressione di CREB, e che la metilazione del suo promotore contribuisce alla trasformazione 
leucemica mieloide. Inoltre abbiamo identificato un sottogruppo di geni target di CREB che 
rappresenta un nuovo network trascrizionale coinvolto nella trasformazione tumorale, aprendo la 
strada a nuovi possibili studi funzionali su questi geni.  
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Con queste premesse, abbiamo deciso di sviluppare un modello in vivo di zebrafish per 
valutare il ruolo di CREB e dei suoi geni target nell’insorgenza della leucemia. La scelta di questo 
organismo modello è stata dettata dai numerosi vantaggi che presenta, che negli ultimi anni lo hanno 
portato ad essere ampiamente usato sia in studi di sviluppo che nella ricerca sul cancro. Infatti, lo 
zebrafish possiede alta capacità rigenerativa, ha uno sviluppo embrionico rapido, allo stadio di 
embrione è trasparente, e ha numerose possibilità di manipolazioni genetiche. Nel presente studio, per 
sovra esprimere CREB nella linea mieloide di zebrafish, abbiamo iniettato un plasmide codificante 
CREB umano sotto il controllo del promotore pu.1 all’interno di uova fertilizzate allo stadio 
unicellulare, L’analisi dei geni che regolano l’ematopoiesi, ha dimostrato che negli embrioni a 24 e 48 
ore di vita, la sovra espressione di CREB portava ad una perturbazione ematopoietica, e ad 
un’alterazione di espressione genica dei target di CREB, conferendo una progressione del ciclo 
cellulare. A partire dai 6 mesi dall’induzione dell’espressione di CREB, le popolazioni cellulari del 
midollo mostravano una lieve dismielopoiesi, caratterizzata prevalentemente da un’aumentata quota di 
mielociti e monociti.Tra i 9 e i 14 mesi dall’induzione esogena di CREB, i pesci manifestavano 
un’espansione addominale e dorsale, che ad una valutazione morfologica si è rivelata una massa 
addominale formata da cellule clonali con capacità infiltranti. E’ stato provato che le cellule della 
massa originavano dalle cellule che sovra esprimevano CREB umano, e possedevano alta capacità 
proliferativa. Queste cellule avevano infiltrato tessuti ed organi, quali branchie, tessuto adiposo e 
muscoli. Ad un esame morfologico, le cellule della massa apparivano del tutto simili alle cellule che 
popolavano il midollo dei pesci malati, con una completa perdita dei mielociti ed una preponderanza 
di monociti, confermando un disordine mieloproliferativo. Questi risultati mostrano che gli zebrafish 
sovra esprimenti CREB hanno manifestato la stessa dismielopoiesi già descritta in vitro e nei topi 
transgenici sovra esprimenti CREB, probabilmente mediata da un’elevata espressione dei geni target 
di CREB. La lunga latenza dell’insorgere della malattia suggerisce che potrebbero esserci ulteriori 
eventi che inducono la trasformazione tumorale. 
In conclusione, il modello di zebrafish creato in questo lavoro descrive una patologia 
mieloproliferativa indotta da CREB, e può rappresentare uno strumento utile per poter studiare il ruolo 
di CREB nella leucemogenesi. Inoltre, l’utilizzo di ICER e del miR-34b come oncosoppressori, e lo 
screening di nuovi composti che interferiscano con l’attività di CREB e con l’espressione dei suoi geni 
target, può aprire la strada a nuove opportunità terapeutiche. 
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CHAPTER 1 
_______________________ 
 
INTRODUCTION 
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HEMATOPOIESIS 
The earliest cell in hematopoietic hierarchy is the pluripotent hematopoietic stem cell (HSC), 
which has self-renewal capacity and multi-lineage hematopoietic potential, giving rise to all 
hematopoietic lineages. HSC existence was demonstrated by serial bone marrow transplantation 
(BMT) experiments, where all hematopoietic lineages could be reconstituted in lethally irradiated mice 
[1]. According to the current model of hematopoiesis, maturing HSCs give rise to multipotent 
progenitors, which also possess stem cell-like properties, but exhibit a progressive restriction of 
cellular fate, that in turn differentiate into either common myeloid or common lymphoid progenitor 
cells (CMPs and CLPs, respectively), which are lineage-restricted. CMPs differentiate into either 
granulocyte–macrophage progenitors (GMP) or megakaryocyte-erythrocyte progenitors (MEP), which 
eventually differentiate into functional end cells, such as granulocytes, macrophage, platelets and 
erythrocytes. CLPs further differentiate into pro-B and pro-T cells, which give rise to terminally 
differentiated B cells and T cells, respectively (figure 1). Elucidation of the cellular hierarchy in 
human hematopoiesis provides a valuable resource for mapping the key regulatory networks that 
control blood differentiation and lineage commitment. Lineage commitment could be induced either 
by extracellular factors, including cytokines, direct cell-cell interactions, or other environmental 
signals. Alternatively, it could be induced by intrinsic mechanisms: among these, transcription factors 
(TFs), owing to their capacity to simultaneously activate and repress hundreds of genes, have been 
shown to be master regulators of lineage commitment fates. 
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Figure 1. Hematopoiesis development: from a totipotent stem cell to mature hematopoietic cells, through multipotent 
progenitors and committed progenitors stages. Legend: LT-HSC: long term hematopoietic stem cell; ST-HSC: short term 
hematopoietic stem cell; CMP: common myeloid progenitor; CLP: common lymphoid progenitor; MEP: megakaryocyte-
erythrocyte progenitor; GMP: granulocyte–macrophage progenitor [2] 
 
HEMATOPOIETIC DISORDERS AND IMPAIRED MYELOPOIESIS 
Hematopoiesis is a tightly regulated process; studies on the development of hematopoietic 
cells led to the discovery of proteins that regulate cell viability, growth and differentiation of diverse 
lineages and to the identification of the molecular basis underlying normal and aberrant cell 
development in blood-forming tissues. These regulators include principally cytokines, colony 
stimulating factors and interleukins. The evolution process needs a spatial and temporal regulation of 
cytokines in order to induce the right lineage commitment. Cytokines can induce the expression of 
transcription factors and can thus ensure the autoregulation and transregulation of this maturation 
process. Genetic abnormalities involving regulators of hematopoiesis can impair the proliferation or 
block the differentiation of subtypes of hematopoietic cells. So, the alteration of specific gene and 
protein expression programs, may lead to the development of a hematologic disease.  
The pathogenetic event that occurs during hematopoiesis can affect stem, precursors, or 
committed cells at the lymphoid or the myeloid lineage, leading to a different disease with a different 
outcome.  
The interest of this work is addresses to myeloid disorders.  
According to the 2008 World Health Organization (WHO), the classification of hematopoietic 
disease includes 5 subgroups of myeloid neoplasms: 
1- Myeloproliferative neoplasms (MPNs), which are characterized by excessive 
cell proliferation, 10-20% of blast count and risk of AML evolution. They originate from 
genetically transformed hematopoietic stem cells that retain the capacity for multilineage 
differentiation and hematopoiesis [3].  
2- Myeloid neoplasms with eosinophilia and abnormalities of PDGFRA, 
PDGFRB, or FGFR1, that are featured by blood and bone marrow eosinophilia in which the 
tumor cells harbor a gene fusion between PDGFRA and an adjacent gene locus termed 
FIP1L1, manifested as overexpression of PDGFRA receptor tyrosine kinase activity, which 
leads to cell proliferation. 
3- Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs), which are rare 
de novo myeloid neoplasms that exhibit some clinical, laboratory, or morphologic findings of 
myelodysplastic syndrome, and others typical of myeloproliferative neoplasm. They present 
cytopenias and cell dysplasia of at least 1 lineage. The bone marrow of patients with 
MDS/MPNs is characteristically hypercellular. By definition, the percentage of blasts in the 
blood and the bone marrow must be less than 20% [4].  
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4- Myelodysplastic syndrome (MDS), a clonal disorder characterized by 
inefficient dysplastic hematopoiesis, peripheral blood cytopenias and risk of progression to 
AML. It is featured by defective differentiation of hematopoietic cells, which in turn lead to 
peripheral blood cytopenia and, in case of AML evolution, to the expansion of the abnormal 
clone. A variety of molecular abnormalities have been demonstrated in MDS, reflected as 
phenotypic heterogeneity. MDS is called either primary or secondary MDS: primary MDS is 
much more common than secondary MDS and may also be called de novo MDS; secondary 
MDS occurs because of damage to the DNA from chemotherapy or radiation therapy 
previously given to treat another medical condition and it is often associated with more 
complex chromosomal abnormalities.  
5- Acute Myeloid Leukemia (AML), which represents a group of heterogenic 
hematopoietic cancers characterized by clonal proliferation of neoplastic myeloblasts arrested 
in diverse differentiation stages, with loss of normal hematopoietic function and accumulation 
of leukemic blasts or immature forms in the bone marrow (> 20% blast count), peripheral 
blood and occasionally in other tissues. The leukemic blasts accumulation leads to a number 
of systemic consequences including anemia, bleeding and increased risk of infection. In the 
WHO scheme, a myeloid neoplasm with 20% or more blasts in the bone marrow (BM) or 
peripheral blood (PB) is considered to be acute myeloid leukemia (AML) when it occurs de 
novo, evolution to AML when it occurs in the setting of a previously diagnosed 
myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN), or blast transformation in a previously diagnosed myeloproliferative neoplasm 
(MPN) [5]. 
 
CELLULAR AND MOLECULAR ORIGINS OF AML 
AML accounts for approximately 20% of acute leukemias in childhood; significant progresses have 
been made in its treatment over the past 40 years, achieving survival rates increase from < 20% in 
1970 to approximately 60% nowadays, considering children treated on clinical trials in developed 
countries [6]. The advance in survival rate is due to a better risk classification, adaptation of treatment 
based on patient’s response to therapy and improvements in allogenic hematopoietic stem cell 
transplantation. However, most of the AML cases continue to pose a therapeutic challenge, therefore 
understanding the pathogenesis of this disease and the identification of molecular abnormalities would 
lead to the development of a better rationally designed therapy [7]. Myeloid disorders present a 
heterogeneous nature reflected by differences in morphology, immunophenotype, as well as 
cytogenetic and molecular aberration; this is due to the diversity of myeloid precursors susceptible to 
malignant transformation, and the multiplicity of genetic or epigenetic events that can lead to the 
transformation. Despite this heterogeneity, the various subtypes seem to share the activation of 
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common pathways leading to leukemogenesis. It has been established that AML development requires 
at least two types of cooperative genetic events: type I and type II aberrations. Type I aberrations 
concern mutations in hotspots of specific genes involved in signal transduction pathways, resulting in 
uncontrolled cell proliferation and/or survival of leukemic cells, including FLT3, KIT, NRAS, KRAS, 
PTPN11 mutations. Type II aberrations concern chromosomal rearrangements of transcription factors 
resulting in impaired differentiation of leukemic cells, including PML-RARα [t(15;17)(q22;q21)], 
AML1-ETO [t(8;21)(q22;q22)], CBFB-MYH11 [inv(16)(p13q22)/t(16;16)(p13;q22)] and 11q23/MLL-
rearrangements [8]. Moreover, cell that undergoes transformation may arise from a self-renewing 
hematopoietic stem cell, or it may come from a more differentiated myeloid progenitor that acquires 
the ability to self-renew upon leukemogenic event.  
Identifying specific leukemogenic aberrations may guide the development of targeted therapy 
approaches for selected patient groups.  
 
Genetic aberrations 
Genetic lesions consist of gene mutations and chromosome modifications, which mainly 
include entire or partial chromosomal amplifications, deletions, inversion, or translocation, as 
well as, point mutations. Nowadays we can consider that more than 90% of pediatric AML 
patients have at least one known genomic alteration (figure 2). In particular, chromosomal 
aberrations are molecularly detectable in about half of AML pediatric cases, and are often 
balanced translocations. These genetic lesions create fusion proteins that often results in loss-
of-functions or gain-of-function mutations. Depending on which pathway is affected, they can 
cause a differentiation block (preventing physiological hematopoietic development), or an 
aberrant enhanced proliferation [7]. Identification of chromosomal abnormalities has been 
largely demonstrated to have diagnostic and therapeutic implications. In particular, patients 
affected by t(8;21), t(15;17), or inv(16) have usually a better prognosis than patients affected 
with deletion of chromosome 5, 7 (5-,7-), del(5q) [9]. Interestingly, MLL gene located at 
11q23 has been found rearranged with a variety of partner genes, bearing to the most 
heterogeneous of all genetic subtypes of leukemia.  
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Figure 2. Estimated frequency of genetic abnormalities in childhood AML. Left panel demonstrates the most common 
karyotypic alterations. Right panel shows mutation profile in patients without cytogenetic abnormalities (normal karyotype). 
67% of those in the normal karyotype population have one of the known mutations; thus, more than 90% of all children with 
AML have at least one known genomic abnormality [8].  
 
In the last decade, the molecular detection of several mutations have increased the knowledge 
of the AML genetic leading to a considerable improvement of therapy protocols and patient 
survival. Of relevance there are mutations at tyrosine kinase receptors, that often impart 
proliferative and survival signals. FLT3-ITD is the most important one because it occurs in up 
to 15% of pediatric AML de novo. This mutation involves a duplication of the internal 
juxtamembrane domain of the FLT3, leading to constitutive receptor activation (incidence of 
the 5 to 10 % in 5-to-10 year old patients), and it is correlated with high risk stratification for 
its poor prognostic value.. NPM1 mutation accounts up to 20% of childhood leukemia with 
normal karyotypes, resulting in aberrant cytoplasmic translocation of this nucleolar 
phosphoprotein, which normally is involved in ribosome biogenesis and control of centrosome 
duplication [10]; subgroup characterized by this mutation as single aberrancy is associated 
with a favorable prognosis, whereas it has poor prognostic value if associated to FLT3 
mutations. Loss-of-function mutation in CEBPA, a key leucine zipper transcription factor 
critical for regulate the differentiation of myeloid precursors, accounts for 15% to 20% of 
pediatric AML, and predicts a favorable prognosis in AML patients with normal cytogenetics 
[11]. Inactivating mutation of Wilms tumor (WT1) transcription factor gene is reported in 8% 
to 12% of AML patients, but without independent prognostic significance in predicting 
outcome in pediatric AML [8, 12].  
Recent genome-wide and sequencing analyses are revealing new chromosomal and point 
mutations respectively, opening for a lot of new data to be analyzed and prognostically 
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classified. First results indicate that AML contains fewer genetic alterations than do other 
malignancies. Pediatric AML in particular contains few genomic alterations, with only 2.4 
somatic copy-number alterations per leukemia and no copy-number alterations in about one-
third of cases, suggesting that the development of AML may require fewer genetic alterations 
than other malignancies [13]. Interestingly, genome sequencing data are mainly from adult 
AML, whose mutations frequency is demonstrated to be different from those found in 
pediatric cases, such as IDH1, IDH2, DNMT3A, nucleophosmin NPM1 [14-16]. 
 
miRNA 
microRNAs are highly conserved genes of 70-80 nucleotides in length, coding for mature 18-
25 oligonucleotides, not proteins. Although miRNA genes represent approximately 1% of the 
genome [17], there have been estimated that 30% of all human genes are regulated by at least 
one miRNA [18]. miRNAs achieve this regulation by binding to the 3’-untranslated region 
(UTR) of their target mRNA with partial complementarity, inducing translational repression 
[17]. MiRNAs are processed from a larger stem-loop precursor (pre-miRNA) by the enzyme 
Dicer, generating double-stranded RNA (dsRNA) intermediates. One strand encodes the 
mature miRNA that binds to 3’-UTR region of its target-mRNA (figure 3). In contrast, the 
other strand (denoted as miRNA*- strand) is believed to be non-functional and is degraded 
upon its release [19].  
 
Figure 3. Biogenesis and epigenetic regulation of the expression of miRNAs. miRNA genes are processed by 
DROSHA and DICER enzymes, and one strand of mature miRNA binds to 3’-UTR region of its target mRNA, 
whereas the other strand is degraded. miRNAs expression can be affected by transcription factors, genetic 
alterations or epigenetic alterations [20]. 
 
miRNAs have an important role in cell processes such as development, proliferation, 
differentiation, apoptosis, and tumorigenesis as well [20]. miRNAs manage the control of 
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multiple pathways, including both lymphoid and myeloid lineages commitment in 
hematopoietic system. For example, miR-181 was one of the first miRNA demonstrated to be 
preferentially expressed in hematopietic tissue, whereas miR-328 has been found to stimulate 
differentiation of the myeloid lineage through C/EBPα promoted expression. Having such 
important role in hematopoiesis homeostasis, deregulation of miRNAs is involved in altered 
hematopoiesis. The first evidence of the involvement of miRNA in human hematopoietic 
cancer was described by Calin et al., who showed the downregulation of miR-15a/16-1 
because of a genomic deletion in CLL patients [21].  
To unveil which miRNAs are dysregulated in acute leukemia, miRNA genome wide-
expression studies have been conducted, revealing that miRNA expression patterns of acute 
leukemia patient’s are different from that of normal hematopoietic cells, and also within 
diverse acute leukemia subtypes. In fact miRNA expression levels are associated to gene 
expression profile and to AML mutational status. In fact in 2009 Zhang et al [22], performing 
a genome-wide miRNA expression analysis, demonstrated that the miRNA expression 
signature could accurately discriminate pediatric AML. They identified significantly 17 up-
regulated and 18 down-regulated miRNAs; among the up-regulated miRNAs, the highly 
expressed ones were miR-100, miR-125b, miR-335, miR-146a and miR-99a, which were 
diverse from those highly expressed observed in pediatric ALL or adult AML analysis. 
Moreover, the clustering based on these miRNAs expression in pediatric AML identified three 
groups that coincided exactly with the morphologic French-American-British (FAB) 
classification of AML lineage subtypes: miR-355 up-regulation correlated with FAB-M1, 
miR-126 up-regulation correlated with FAB-M2, and miR-125a up-regulation correlated with 
FAB-M3.  
 
Epigenetics  
Although gene and microRNAs expression signatures can accurately discriminate cases with 
specific chromosomal translocations and identify novel subsets of AML, there are evidences 
that knowledge of genetic profile is not sufficient to fully understand cancer biology. Some of 
the differences observed in gene expression studies are beginning to be understood in terms of 
epigenetic regulation of chromatin function.  
Epigenetic mechanisms are described as heritable changes in cell phenotype without alteration 
of cell genotype. The two most widely studied epigenetic mechanisms are DNA methylation 
and histone modification. DNA methylation is a covalent modification that typically occurs at 
CpG dinucleotides, located in small genome regions known as CpG islands, and can be 
catalyzed by different enzymes, including DNMT1, DMNT3a/b. Most CpG islands are located 
in the promoter region of almost half of the genes, and are unmethylated in normal cells, 
whereas they can be methylated in tumor cells, driving an inappropriate transcriptional 
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silencing of these genes, by direct interference of transcription factors binding to target sites 
[20]. Histone modification consists of post-translational modification of histone tails, 
including acetylation, methylation, phosphorylation, ubiquitination, sumoylation [20]; these 
alterations impact chromatin structure and regulatory factor accessibility hereby altering 
chromatin structure, and can lead either to a closed chromatin conformation, thus blocking the 
access of regulatory proteins to cognate DNA elements, or to the disruption of contacts 
between nucleosomes to increase chromatin accessibility [23].  
Altered epigenetic modifications are important players in the pathogenesis of AML. Aberrant 
activity of post-translational modification enzymes probably causes abnormal gene expression 
in hematopoietic precursors that contribute to the cell differentiation arrest of AML [24]. A 
central role for epigenetic dysfunction in AML is supported by the observation of mutations 
and translocations in genes involved in these processes, such as TET2, DNMT3, IDH1, IDH2, 
and the histone H3K4 methyltransferase gene (MLL), even if there is a difference between 
mutation found in adult and pediatric AML. An excellent example are MLL rearrangements 
that are frequent in children younger than 2 years, then decreasing in adultness; whereas 
IDH1, IDH2, DNMT3A mutations are more common in adult AML than in childhood [6]. 
Several studies revealed that aberrant epigenetic modifications, particularly DNA 
hypermethylation of genes promoters, may affect miRNAs expression in acute leukemias. In 
B-ALL an extensive analysis of genomic sequences of miRNA genes has shown that around 
half of them are frequently within CpG islands rich DNA regions,, suggesting that they could 
be subjected to this regulatory mechanism. Analysis from different laboratories showed that 
miRNAs subjected to aberrant hypermethylation were associated with miRNA downregulated 
expression, both in ALL and AML,, and that their expression could be reverted by treating 
with demethylating agents such as 5-Aza-2’-deoxycytidine. Importantly, miRNAs methylation 
profile has demonstrated to be an important prognostic factor in ALL patients (the methylated 
patients showed a significantly higher relapse and mortality rate), and miRNA 
hypermethylation to be an independent adverse prognostic factor for disease free survival and 
overall survival, also by multivariate analysis [25].  
 
Transcription Factor alterations 
Tanscription factors (TFs) are proteins that contain one or more DNA-binding domains 
(DBDs), through which they bind to specific sequences of DNA in the promote region of the 
genes that they regulate, in response to various stimuli. Through this interaction, TFs control 
gene transcription by activating or repressing the transcription, either by direct recruitment of 
RNA polymerase, or by forming multiprotein enzymatic complexes together with other 
cofactors, which facilitate or inhibit gene transcription by modification of chromatin [26]. TFs 
have a crucial role in physiological cell activity, including hematopoiesis, development, 
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proliferation, apoptosis, survival and differentiation, and they respond to intracellular stimuli 
or environmental signals controlling transcription of diverse genes. Because of the importance 
of their role, they are tightly spatially and temporally regulated. Disruption of this strict 
control may lead to neoplastic transformation and tumor onset: numerous genetic and 
epigenetic aberrations result in alteration of transcription factors critical for normal 
hematopoiesis, supporting their key role in hematopoietic homeostasis maintenance. For 
example, the CCAAT/enhancer binding protein alpha (C/EBPα) transcription factor, which is 
fundamental for granulocytic differentiation, regulation of myeloid gene expression and 
growth arrest, has been found impaired in AML. There are diverse mechanisms through which 
C/EBPα function is reduced or disrupted: suppression of transcription, post-transcriptional 
regulation, post-translational modification or gene mutation. All of these events, lead to both 
affected cell cycle regulation and granulocyte differentiation, driving malignant 
transformation [27].  
 
cAMP RESPONSIVE ELEMENT BINDING PROTEIN (CREB) 
Among the variety of TFs, the cAMP response element (CRE) binding protein (CREB) has been well 
characterized. CREB has been localized to human chromosome 2q32.3-q34 [28] and encodes a nuclear 
transcription factor of the CREB/CREM/ATF1-1 basic leucine zipper (bZIP) family. It regulates gene 
expression principally following activation of cAMP-dependent cell signal transduction pathways. It 
binds to a specific regulatory sequence on its target genes promoter, called CRE sequence, a 
palindromic consensus sequence 5’-TGACGTCA-3’, or to the half CRE site (CGTCA/TGACG). 
CREB is a modular protein that contains a conserved structural motif formed by the leucine zipper at 
the C-terminus of the protein, through which CREB homodimerizes or heterodimerizes on its DNA 
target sequence; a basic lysine- and arginine-rich domain amino-terminal to the leucine zipper, through 
which DNA binding is mediated; two glutamine-rich domains (Q1 and Q2); a kinase-inducible domain 
(KID, residue 100-160), that contains serine 133 residue (Ser133), a pivotal residue whose stimulus-
induced phosphorylation mediates activation of CREB [29] (figure 4).  
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Figure 4. Structure of CREB. The glutamine-rich domains (Q1 and Q2) and the bZip region (BD and LZ) are indicated in 
addition to the P-box (the KID domain). Phosphorylation at this serine residue turns CREB into activate form, through the 
interaction with the co-activator CBP. Ser-133 has been shown to be phosphor-acceptor site for various kinases [30].  
 
Ser133 is phosphorylated by various kinases, mostly by cAMP-dependent protein kinase A (PKA), in 
response to various stimuli such as growth factors (mast/stem cell growth factor, basic fibroblast 
growth factor and granulocyte-macrophage colony-stimulating factor), neurotransmitters, stress 
signals that increase intracellular cAMP or calcium levels [31, 32]. CREB phospholylation promotes 
its interaction with a number of transcription coactivators, especially the CREB-binding protein 
(CBP), and p300 [33, 34]. CBP and p300 are nuclear proteins that serve as molecular bridge and allow 
transcription factor to recruit and stabilize the RNA polymerase II (Pol II) transcription complex at the 
TATA box. In addition, CBP and p300 through their acetyltransferase (HAT) activity contribute to 
CREB-mediated transcription by affecting chromatine structure, acetylating histone lysine residues, 
yielding a more accessible DNA template to the transcriptional machinery. CREB activity is also 
regulated via phosphorylation independent mechanisms, through a family of cytoplasmic coactivators 
known as transducers of regulated CREB activity (TORCs), which bind to the bZip domain and 
strongly activate CREB transcription [35]. Interestingly, mammalian CREB has CREs in its promoter 
region, giving rise to a positive feedback loop through which CREB enhance its own transcription 
[36].  
 
CREB physiological role 
Studies have demonstrated that CREB is activated in response to different stimuli, and it has 
the ability to enhance the expression of up to 5000 putative genes. It is ubiquitously expressed 
in somatic cells of human tissues, and is critical for a variety of cellular processes including 
proliferation, differentiation and adaptive response [37, 38]. Among different tissues in which 
it is activated, CREB has an important role in the brain, where it controls learning and 
memory formation, and contributes to neuronal adaptation to drug of abuse. In the liver, 
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CREB activity is important for hormonal control of metabolic processes, including 
gluconeogenesis, by regulating glucagon and insulin hormones [39]. In pancreas β-cells, 
CREB is a key transcriptional element for the maintenance of an efficient glucose sensing, 
insulin exocytosis and β-cell survival [40]. In endocrine tissues, cAMP pathway is crucial for 
normal development of both the thyroid and pituitary glands, thus a regular CREB activity is 
required for the development and homeostasis of these endocrine tissues [41]. In pinealocytes, 
CREB phosphorylation regulates the stimulation of melatonin biosynthesis: the connection 
between CREB phosphorylation and melatonin concentration suggests a relevant CREB’s role 
in the circadian clock [42]. Another important role of CREB is found in Sertoli cells, the 
somatic cells that populate the seminiferous tubules in testis. CREB fluctuating levels regulate 
transcription of genes essential for proper germ cell differentiation [43]. In hematopoiesis, 
CREB is highly expressed in stem cells and uncommitted progenitors of both human and 
murine bone marrow cells [26]. Indeed, transduction of primary HSCs with lentiviral CREB 
shRNA resulted in decreased proliferation, cell cycle abnormalities and inhibition of CREB 
transcription. Nevertheless, transplantation of bone marrow cells transduced with CREB 
shRNA in irradiated mice led to decreased committed progenitors, without effects on long-
term engraftment, suggesting that CREB is important but not essential for normal HSCs’ 
functions [26]. Importantly, CREB has a complex action on cellular proliferation and cell 
cycle control: it has been shown to positive regulate proliferation alterating cell cycle through 
cyclins A1 and D1 upregulation, to enhance S-phase entry and to promote growth-factor-
independent proliferation [26, 44].  
 
CREB in cancer 
One unifying theme in oncogenesis is that apparently unrelated tumors can activate the same 
oncogenic signaling pathways using different strategies. CREB has a significant impact on 
cellular growth, proliferation and survival, and to overturn the cellular strict control of these 
processes, tumor cells have developed various mechanisms to achieve constitutive activation 
of CREB, including chromosome translocations, gene amplification, interaction with viral 
oncoproteins, and inactivation of tumor suppressor genes. Direct CREB implication in cancer 
was first demonstrated in clear-cell sarcomas of the soft tissues (CSSTs), where it has been 
identified a CREB-involving translocation, Ewing’s sarcoma gene EWS-CREB fusion gene, 
which lead to a constitutive activation of CREB [45]. Many other evidences about indirect 
CREB upregulation and tumor onset have been found. Among these, two oncogenic 
retroviruses, such as human T-cell leukemia virus (HTLV-I) and Hepatitis B virus (HBV), 
which cause T-ALL and hepatocellular carcinoma respectively, have been shown to promote 
cellular transformation by constitutively activating CREB, thus enhancing CREB target gene 
expression [46, 47]. Recently, evidences of CREB involvement in the neural stem/progenitor 
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cell (NSPC) survival, differentiation and proliferation have been demonstrated, and a new role 
for CREB in development and growth of brain tumors has been established [48]. Considering 
endocrine tissues, cAMP levels in adrenocortical carcinoma, characterized by mutations in the 
gene encoding phosphodiesterase (PDE) 11A4, resulted elevated, and consequently a 
constitutive CREB phosphorylation was found. Recently, despite the absence of mutations in 
known genes, abnormalities of cAMP signaling have been found in both bilateral adrenal 
hyperplasias (BAHs) and cortisol-producing adenomas (CPAs): these findings suggest that 
constitutive activation of CREB signaling might be one contributory factor in the initiation 
and development of adrenocortical tumors [49]. CREB plays a role also in prostate cancer, 
where p21-activated kinase 4 (PAK4) has been shown to enhance the transcriptional activity 
of CREB independent of Ser133 phosphorylation. This study also indicated a significant 
correlation between impaired tumorigenicity and decreased expression of CREB together with 
its targets, included BCL-2 and CYCLIN A1 [50]. In non-small cell lung carcinoma (NSCLC) 
lines, expression levels of mRNA and protein of CREB and phosphorylated CREB (p-CREB) 
were significantly higher than in the normal human tracheobronchial epithelial cells [51]. 
Moreover, a relation between nicotine treatment and upregulation of α-4 and α-7 subunits of 
nicotine acetylcholine receptors (nAChRs) has been found, highlighting that nicotine abuse 
brings to activation of cAMP signaling, and in turn to CREB activation, promoting lung 
cancer growth [52]. Moreover, CREB coactivators TORCs have also been found deregulated 
in diverse type of cancer. In salivary gland tumors a recurring t(11;19)(p21;p13) translocation 
generates a TORC1-Mastermind-like 2 (MAML2) fusion gene, which activates the 
transcription of CREB target gene, which in turn leads to cell transformation. Importantly, the 
transforming activity of TORC1-MALM2 was markedly reduced by blocking CREB binding 
to DNA [53]. TORC1-MAML2 was also found in other types of cancer related to salivary 
gland tumor: Warthin’s tumor [54] and clear cell hidradenoma [55].  
 
CREB in AML 
Among the variety of cancers, CREB has been shown to have a role in transformation of 
hematopoietic cells. In 2005 Shankar et al. demonstrated that the majority of ALL and AML 
patients overexpressed both protein and mRNA levels of CREB two- to threefold in the blast 
cells of the bone marrow at diagnosis and relapse, but not in remission and non-leukemic 
controls. Moreover AML patients that overexpress CREB were associated with an increased 
risk of relapse and a decreased event-free survival compared to patients with normal 
expression of CREB [44]. Further studies demonstrated that enforced expression of CREB 
promoted growth and survival in leukemia cells, whereas its downregulation lead to 
suppression of myeloid cell proliferation and survival. Transgenic mice overexpressing CREB 
in macrophage/monocyte lineage were shown to develop a MDS/MPN with higher white 
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blood counts and aberrant myelopoiesis in both the bone marrow and spleen after one year, 
but not leukemia, suggesting that CREB contributed to leukemic phenotype through 
upregulation of its downstream target genes, but was not sufficient to complete transformation 
into leukemia [44].The involvement of CREB in leukemia was then confirmed by a study 
performed on a large cohort of pediatric ALL and AML patients at diagnosis. This study 
revealed that 84% of patients with ALL and 66% patients with AML significantly 
overexpressed phosphorylated and thus active CREB protein at diagnosis, but not during 
remission nor in nonleukemic controls [56]. Furthermore, CREB was found to bind CRE 
region exclusively in samples at diagnosis of AML because of the lack of its competitor at 
CRE sites, the inducible cyclic AMP early repressor (ICER). 
In mammals, ICER is a basic leucine zipper (bZIP) family member, generated by alternative 
splicing of cAMP responsive element modulator gene (CREM). ICER is a transcription 
repressor, because it conserves the DNA-binding domain but lacks the transactivation domain 
[57]. As a result, it recognizes and binds the CRE consensus region, and homodimerizes or 
heterodimerizes with CREB repressing transcription of target genes. ICER promoter region 
contains tandemly repeated CREs, resulting in rapid and strong induction upon activation of 
cAMP pathway. ICER competes with CREB for its own promoter occupancy, generating a 
negative feedback that is important for correct cAMP-dependent gene expression in different 
tissues [58]. Analysis of ICER expression revealed that it was downregulated at diagnosis but 
was significantly increased in remission and control samples [56]. Further studies showed that 
ICER restoration in leukemic cell lines gave rise to a significant lower number of colonies in 
in vitro, compared to control cells. In these transfected cell lines, chromatin 
immunoprecipitation experiments showed that ICER recognized CRE elements and thus 
contrasted CREB on activating gene expression [59]. In vivo experiments revealed that ICER-
transfected leukemic cells lowered invasion capability when inoculated in mice, and decreased 
bone marrow angiogenic potential [59].  
Although CREB is overexpressed in leukemia, the underlying mechanisms that lead to the 
increased CREB levels remain largely unknown. Recently, miRNAs have emerged as 
regulators of multiple transcription factors and pathways, with 30% of human genes that 
possess a conserved miRNA binding site. The analysis of CREB 3’UTR region has highlighted 
a miRNA consensus sequence, confirmed to be the miR-34b binding site. Indeed, analysis of 
miR-34b expression in AML cell lines revealed low expression levels compared to healthy 
bone marrow, in agreement with low of the miR-34 family members expression in other 
human cancers [60]. miR-34b downregulation was also found in AML patients at diagnosis, 
and correlated with CREB upregulation. The cause of miR-34b low expression was found to 
be the hypermethylation of its promoter, which in contrast was not found in normal bone 
marrow samples, indicating this epigenetic event an AML associated phenomenon. The 
 21 
restoration of miR-34b in leukemic cell lines showed a direct interaction with the CREB-
3’UTR, leading to a modulation of CREB protein and consequently to a lowered CREB target 
gene expression in vitro, which in turn inhibited cell growth, proliferation and clonogenic 
potential [61]. 
 
ZEBRAFISH in vivo MODEL  
In order to decipher pathogenesis of various cancer types, included leukemia, a number of in vivo 
models have been developed. Among these, the mouse provides a powerful model system that 
recapitulates many aspects of human genetics, anatomy, physiology and biochemistry; however its 
capacity for the assessment of embryonic hematopoiesis, as well as for large-scale chemical screens 
remains limited. On the contrary, simple organisms, such as yeasts and flies, allow an extraordinary 
amount of genetic manipulations, facilitating gene discovery and pathway analysis, but they have 
obvious limitations given to disparate genetics from vertebrates and humans. Furthermore, cancer 
malignancies are not seen in flies and worms. In contrast, a full spectrum of malignant disease is found 
to occur naturally in teleost, including leukemia, making these organisms interesting as a model for 
studying vertebrate biology [62].  
The zebrafish, Danio rerio, is a tropical freshwater fish that possesses approximately 75% 
conservation to human genome [63]. The zebrafish within the past three decades has emerged as an 
excellent vertebrate organism in basic research because of its numerous advantages. Principally, it has 
a high regenerative ability, laying hundreds of eggs in each clutch, which are fertilized externally, 
becoming transparent, allowing easy genetic manipulation, a characteristic that makes zebrafish a 
convenient research model species. Fertilized eggs, kept at the ideal temperature of 28.5 °C, 
immediately begin their rapid embryonic development, which in 36 hours post fertilization (hpf) leads 
to appearance of precursors to all major organs. Embryos transparency permits direct visualization of 
organogenesis and tissue formation. Sex determinants are not clearly understood, and the sex of 
juveniles cannot be distinguished except by dissection [64]. The zebrafish possesses a great ability of 
genetic manipulations, facilitating novel gene discovery as well as detailed genetic pathway studies, 
chemical screens and assessment of organogenesis. Gene knockdown or gene overexpression studies 
can be rapidly performed by morpholinos (chemically modified oligonucleotides that block 
transcription or translation), or DNA plasmid injection into one-cell stage embryos, respectively [62]. 
Due to the relatively short history of the use of zebrafish as a model system, some key tools are still 
missing: one of the main limitations is the absence of hematopoietic cell surface markers. In some 
cases this lack can be compensated by using fluorescent transgenic reporter lines [65].  
 
Zebrafish hematopoiesis 
Several studies of hematopoiesis in zebrafish have provided insights into the conservation of 
essential pathways and genes for normal blood cell development. Zebrafish hematopoiesis is 
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similar to that of mammals and other higher vertebrates, with the formation of analogous 
blood lineages [66]. Zebrafish and mammals have a similar transcription profile in 
hematopoietic tissues, in which highly conserved transcriptional factors regulate the blood 
development. As in mammals, zebrafish demonstrate waves of hematopoiesis. The first or 
primitive wave predominantly produces erythrocytes and some primitive macrophages, and 
arises in two intraembryonic regions: the posterior lateral mesoderm (PLM), that later forms 
the intermediate cell mass (ICM), and the anterior lateral mesoderm (ALM). At 10 hpf, both 
ALM and PLM coexpress hematopoietic and vascular transcription factors, indicating 
initiation of HSC and angioblast (vascular precursor), proving the existence of a bipotent 
hemangioblast. By 18 hpf in ICM region these bipotent cells differentiate in proerythroblasts 
and endothelial cells; in the erythropoietic process, the zinc-finger transcription factor gata1 
have a crucial role [67]. By 24 hpf approximately 300 gata1-positive proerythroblasts in the 
ICM enter in the circulation and mature into erythrocytes. All zebrafish erythrocytes are 
nucleated, opposite to mammalian ones. Similar to those in the ICM, the cells in the ALM 
contribute to both blood and vascular development. By 11 hpf the myeloid-specific 
transcription factor pu.1 is detected in ALM cells, indicating the myeloid commitment of these 
cells, and by 22-24 hpf they mature into macrophages and granulocytes and migrate across the 
yolk sac [64, 68]. The primitive hematopoietic wave is followed by a transient wave in the 
posterior blood island (PBI) site also known as the caudal hematopoietic tissue (CHT), where 
from 24 to 36 hpf erythro-myeloid progenitors arise, which are the first cells that give rise to 
multiple blood lineages. The second or definitive hematopoietic wave begins at 32 hpf, and 
demonstrates an anatomical location shift towards the ventral wall of the dorsal aorta, the 
equivalent of the aorta-gonad-mesonephros (AGM), where the first HSCs arise. Next, HSCs 
are found in the CHT, the equivalent of mammalian fetal liver, and finally by 4 to 5 days post 
fertilization (dpf), HSCs migrate from the AGM and CHT to seed the kidney marrow, the 
equivalent of the mammalian bone marrow [69-71], and thymus for lymphopoiesis. The 
transcription factor runx1 is a key regulator of definitive hematopoiesis and is expressed in 
HSCs [67] (figure 5). 
Many of the morphologic and cytologic features of hematopoiesis are conserved between 
zebrafish and mammals. In the matter of myelopoiesis, zebrafish have two granulocyte 
lineages: the first resembles mammalian neutrophils, in spite of two or three lobes segmented 
nuclei instead of four or five lobes found in human cells; the other lineage possesses features 
of both mammalian basophils and eosinophils, with very large granules, but without bilobed 
nuclei characteristics of mammals cells. Monocytes/macrophages show similar morphology to 
mammalian cells, with large nucleus and basophilic cytoplasm, demonstrating phagocytosis 
ability [72]. 
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Figure 5. Spatial and temporal representation of zebrafish hematopoiesis. Different sites of hematopoiesis are 
represented in the top panel. The primitive wave of hematopoiesis (in yellow) consists of hemangioblasts that give rise to 
myeloid (M) and endothelial cells (EC) in the anterior lateral mesoderm (ALM) and to erythroid (E) and ECs in the posterior 
lateral mesoderm (PLM), which later becomes the intermediate cell mass (ICM). The first hematopoietic progenitor cells with 
multilineage potential are found in the posterior blood island (PBI); these erythromyeloid progenitors (EMPs) give rise to 
erythroid and myeloid cells in a transient definitive wave (in pink). The definitive wave of hematopoiesis (in blue) that 
contains long-term self-renewing hematopoietic stem cells (HSCs) originates in the aorta-gonad-mesonephros (AGM). The 
AGM progenitor cells seed the caudal hematopoietic tissue (CHT) and kidney and proliferate to population of HSCs with 
self-renewal potential. Based on the expression patterns of blood-specific markers, erythroid, myeloid, and thromboid (T) 
lineages are found in the CHT. Kidney marrow contains all the different blood lineages. The common lymphoic progenitors 
(CLP) mature into lymphoid T cells (L(T)) in the thymus. The locations of different sites of hematopoiesis are depicted in a 
24 h post-fertilization (hpf) embryo (left) and a 72 hpf larva (right). The timeline for expression of blood-specific markers at 
different sites is shown in the bottom panel. Important blood-specific transcription factors and markers are listed in each box. 
Mesoderm cells (white box and gray arrows) differentiate into four independent populations of blood progenitor cells in the 
ALM, PLM/ICM, PBI, and AGM. Blood circulation begins around 24 hpf (red line and arrow). The AGM progenitors begin 
to enter the circulation around 33 hpf, and by 48 hpf, the CHT and kidney are simultaneously seeded by these progenitors 
(black arrows). The CLPs from the AGM begin to migrate to the thymus around 54 hpf. The CHT serves as an intermediate 
site of definitive blood development, then from larval stage and into adulthood the kidney is the primary site of 
hematopoiesis. The thymus is the site of maturation of lymphoid T cells, however the CLPs, like other blood progenitors in 
the adult, originate in the kidney. ALM, anterior lateral mesoderm; PLM, posterior lateral mesoderm; ICM, intermediate cell 
mass; PBI, posterior blood island; AGM, aorta-gonad-mesonephros; CHT, caudal hematopoietic tissue; HSC, hematopoietic 
stem cell; M, myeloid; EC, endothelial cell; E, erythroid; EMP, erythromyeloid progenitor; CLP, common lymphoic 
progenitor; L(T), lymphoid T cell; L(B), lymphoid B cell; T, thromboid; P, hematopoietic progenitor cell; hpf, hour post-
fertilization [67]. 
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Zebrafish leukemia models 
In the last decade, in addition to hematopoiesis studies, the zebrafish has been increasingly 
used as a vertebrate model for studying hematological disorders. So far, three different 
lymphoblastic leukemia models have been generated in zebrafish. Thomas Look’s group was 
the first to develop a T-ALL model in 44-52 dpf by expressing the mouse c-Myc gene fused to 
the eGFP under the zebrafish recombinase-activating 2 (rag2) promoter, specific for 
lymphocytes. In this model, T-ALL first emerged as a thymic expansion before hematologic 
dissemination [73]. Chen et al. developed a T-ALL model by overexpressing the intracellular 
domain of human Notch1 (ICN1) fused to eGFP. Transgenic fish ICN1-overexpressing 
developed an oligoclonal T-ALL in 11 months, and showed increased expression of Notch 
targets [74]. The only model for B cell precursor ALL was generated by Sabaawy et al. TEL-
AML1 fusion protein has been expressed under an ubiquitous promoter, and B-ALL 
developed in 3% of transgenic zebrafish after a latency of 8-12 months [75]. Among myeloid 
malignancies, only one zebrafish model has been developed so far. Zhuravleva et al. 
constructed a zebrafish model in which a member of MYST histone acetyltransferases (MOZ) 
was fused to TIF2, a member of the p160 nuclear receptor transcriptional coactivator family, 
resembling a rare genetic lesion found in AML. MOZ-TIF2 fusion protein driven by the pu.1 
promoter, developed AML characterized by immature myeloid cells invasion of the kidney 
marrow [76] in only 2 out of 180 injected-embryos after a long latency (14 and 26 months 
after injections), suggesting a likely additional needed event. Others zebrafish models created 
by insertion of fusion genes and gene mutations, led to aberrant myelopoiesis, without develop 
an overt AML. Human AML1-ETO induction in zebrafish led to immature blasts 
accumulation and redirection of erythroid progenitors towards a myeloid cell fate, even if this 
fusion protein alone was insufficient for leukemia induction [77]. Zebrafish tel-jak2 fusion 
gene introduction driven by the pu.1 promoter, resulted in disruption of embryonic 
hematopoiesis as well as expansion of the myeloid compartment [78]. The N-terminal of 
nucleoporin fused to C-terminal of homeobox A9 (NUP98-HOXA9) fusion gene, when 
injected in zebrafish led to a myeloprolifearative disorder with malignant infiltration of 
myeloid cells between 19 and 23 months of age, without developing AML [79]. Mutated 
nucleophosmin (NPM), often found in human AML, when expressed in zebrafish resembled 
aberrant localization to cytoplasm, and took to aberrant hematopoiesis, but failed to develop 
AML [80]. A model to study KRAS was created by Le et al., in which the active form of 
human KRAS (KRASG12D) was expressed ubiquitously in the zebrafish embryos. With a 
short latency, 8% of zebrafish developed a myeloproliferative disorder characterized by an 
expansion of the kidney, with abundant myeloid cells at various differentiation stages [81].  
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ABSTRACT 
Purpose: The Inducible cAMP early repressor (ICER) is found downregulated in acute 
myeloid leukemia (AML), failing to control cAMP response element binding protein (CREB) 
transcriptional activity, recently demonstrated to mediate AML progression. We aimed to characterize 
ICER’s role in drug sensitivity by treating myeloid cell lines and primary AML with chemotherapics. 
Experimental design: The effects on CREB target genes induced by ICER restoration and 
drug treatment were studied by Real Quantitative-PCR (RQ-PCR) and Western blot. Cell cycle and 
apoptosis analysis were performed. Possible ICER evoked pathways were investigated in vitro. The 
mechanism involved in enhanced drug sensitivity was described in primary AML cultures by silencing 
ICER main target genes.  
Results: AML cell lines reduced cell growth and enhanced apoptotic behavior after 
chemotherapy treatment if ICER was expressed. A significant lowered expression of CREB target 
genes involved in cell cycle control (CyA1,B1,D1), and in the mitogen-activated protein kinase 
(MAPK) signaling pathway (ERK, AKT, DUSP1/4) was found after Etoposide treatment. The dual-
specificity phosphatases DUSP1 and DUSP4, directly repressed by ICER, activated p38 pathway 
which triggered an enhanced caspase-dependent apoptosis. The silencing of DUSP1/4 in HL60 
confirmed the same enhanced drug sensitivity induced by ICER. Primary AML cultures, silenced for 
DUSP1 as well as restored of ICER expression, showed DUSP1 downregulation and p38 activation. 
Conclusion: ICER mediates chemotherapy anticancer activity through DUSP1-p38 pathway 
activation and drives cell program from survival to apoptosis. ICER restoration or DUSP1 inhibition 
might be possible strategies to sensitize AML cancer cells to conventional chemotherapy and to inhibit 
tumor growth. 
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INTRODUCTION 
Transcriptional regulation via the cyclic adenosine monophosphate (cAMP) dependent 
pathway is controlled principally by the cAMP response element binding protein (CREB) and by the 
cAMP response element modulator (CREM) (1,2). CREB is a transcriptional activator of the 
downstream target of hematopoietic growth factor signaling, and its role in leukemogenesis was 
recently described (3). CREB was found to be overexpressed in myeloid leukemia cell lines and in 
patients at diagnosis, contributing to disease progression, and to improve tumor proliferation and 
survival in vitro (4-6). The CREM gene generates positive and negative transcription regulators. In 
particular, ICER (inducible cAMP early repressor) is driven by an alternative promoter (P2), which 
directs the transcription of a truncated product (7). Through its bZIP domain, it can either recognize 
cAMP response element (CRE) consensus elements on gene promoters, impeding their transcription, 
or it can dimerize with CREB, impeding CREB phosphorylation of the residue of Serine 133, 
triggering gene repression and CREB destabilization (8-10). Previous studies demonstrated that 
exogenous ICER expression decreased CREB protein levels and induced a lowered clonogenic 
potential in vitro and in vivo, demonstrating its potential role as tumor suppressor in leukemia as well 
as in prostate tumors. ICER was shown to repress many target genes upregulated by CREB in acute 
myeloid leukemia (AML), restoring the normal regulation of the main survival cellular pathways (11-
13). The impact of the restored ICER on leukemic cell activity and its ability to suppress tumors is 
under investigation here. Considerable attention has been focused on the role played by ICER in 
different kinase cascades, specifically in the control of apoptosis. We focused on the MAPK family 
members which included numerous cellular signaling, such as extracellular signal regulated kinase 
(Erk1/2), c-Jun N-terminal kinase (JNK), and p38 known to transmit different types of signals (14,15). 
Erk1/2 acts through mitogenic stimuli promoting cell proliferation, whereas p38 and JNK are stress 
factors related to cell growth inhibition and apoptosis (16,17). The outcome of MAPK activation 
depends on the level and period of the phosphorylation status of the proteins involved, which are 
mostly controlled by a specific family of phosphatases with negative regulatory control ability, called 
dual specificity phosphatases (DUSPs) (18,19). The DUSP proteins family contains several members 
with substrate and subcellular localization specificity (20). In particular, DUSP1/4 target principally 
p38, and many different stimuli are able to activate their activity (21,22). The balance between the 
activation or inactivation of the MAPK mediated by DUSPs modulates the proliferative or apoptotic 
cell phenotype in several tissues. Increased levels of DUSP1 have been found in ovarian carcinoma, 
breast and prostate cancer (23-25). On the other end, we previously demonstrated that CREB 
stabilized extracellular signal regulated kinase (ERK), which is responsible for lowered ICER 
expression levels (11) by driving it to the proteasome (26), permitting overexpression of DUSP1/4 and 
thus influencing MAPKs. These facts highlight an intricate interplay between CREB/ICER 
transcription factors and the signaling of MAPK in the control of myeloid leukemia cell fate (27-29).  
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The aim of this study was to elucidate whether and how the restoration of ICER expression 
leads to increased sensitivity of myeloid leukemic cells to chemotherapy treatment, resulting in 
apoptosis.  
 
MATERIAL AND METHODS 
Cell culture and transfection. HL60, ML2, THP-1 cell lines (American Type Culture Collection, 
MD, USA) was cultured in DMEM (Invitrogen-Gibco, CA, USA) supplemented with 10% heat-
inactivated fetal calf serum (FCS), 100U/ml penicillin and 100 µg/ml streptomycin (Invitrogen-
Gibco). Cell lines were grown in suspension diluted to 500X106/ml , and after 24 h were transiently 
transfected by Nucleofector system from Amaxa GmbH (Cologne, Germany) with 1.5 µg of pEGFP∆-
N1_FLAG-ICERγ or pEGFP∆-N1-EV (the Empty Vector) used as control. We used the stable 
HL60+ICER and HL60+EV cell lines previously described in Pigazzi et al. (11). 
Primary cell cultures. Three untreated AML patients were included in the present study. The study 
was approved by the local Ethics Committee, and samples collected after obtaining written informed 
consent. AML cells were isolated from BM by hemolysis and cultured in DMEM (Invitrogen-Gibco) 
supplemented with 100U/ml penicillin and 100 µg/ml streptomycin (Invitrogen-Gibco), IL-3, IL-6, 
Flt-3 ligand and TPO (Sigma). After 24 h of incubation at 37 ° C, cells were added to 10% heat-
inactivated fetal calf serum (FCS) to be transiently transfected by nucleofection (Amaxa) with 3.5 µg 
of pEGFP∆-N1_FLAG-ICERγ or pEGFP∆-N1-EV. Silencing of DUSP1 was also performed in the 
same cells by using 400 nMol (in 2 ml of total volume) of oligonucleotides (Dharmacon Industries, 
Lafayette, CO), as well as the scramble negative Sirna (Sir-sc) used as control at the same 
concentration. To establish the time of experiments, we observed cell viability. The three patients were 
pediatric, age < 18 years; the FAB classifications were one M4, one M1 and one M5. Two of them had 
normal karyotype; the M4 was inv16-CBFB-MYH11 rearranged. BM infiltration was up to 70%. 
3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay. We performed dose-
dependent studies of VP-16, doxorubicin (doxo) and staurosporine (stauro) by growing cells in the 
presence or absence of increasing concentrations of the drug at 37 °C for up to 72 hours, and reduction 
of the MTT (Sigma-Aldrich, MO, USA) salt was measured. The subtoxic drug dose at which the 
proliferation of cell lines was not significantly affected was 1 µM for VP-16, 0.03 µM for doxorubicin 
and 0.24 µM for staurosporine.  
Fluorescence Microscopy. HL60+ICER and HL60+EV were serum-starved overnight before adding 
1 µM VP-16 for up to 72 hours. To assess time-dependent nuclear morphology perturbations of VP-
16-treated and untreated cells, 5x105 cells were spotted every 24 hours and incubated in 10% FCS-
PBS with DAPI nucleic acid stain (1:1000). The cells were observed at 63/0.75 numerical aperture 
with a Leica DMBL microscope; images were obtained with a Leica DC 300F digital camera (Leica 
Microsystems Ltd., Germany). 
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Cell cycle analysis. HL60+ICER and HL60+EV cell lines were serum-starved overnight and then 
continuously treated with 1 µM VP-16, 0.03 µM Doxo and 0.24 µM Stauro. After 6, 24 and 48 hours, 
5x105 cells were washed twice with PBS, lysed and treated with 50 µg/ml Propidium Iodide (PI) in 1 
ml PBS overnight at 4 °C. Cells were analyzed by using Cytomics FC500 (Beckman Coulter, FL, 
USA). Cycle analyses were performed using Multicycle Wincycle software (Phoenix Flow Systems, 
CA, USA).  
Apoptosis assays. Cell lines were serum-starved overnight and then continuously treated with 1 µM 
VP-16, 0.03 µM Doxo and 0.24 µM Stauro over a 48 hours period. Drugs were solubilized in DMSO, 
which was found to induce less than 0.5 % apoptosis. Cells were stained with annexinV conjugated to 
fluorescein-isothiocyanate (FITC) and PI, according to the manufacturer’s instruction (Boehringer, 
Mannheim, Germany) and analyzed by Cytomics FC500 (Beckman Coulter). To determine caspase 
activation, we used 10 µM Z-VAD-fmk (Sigma-Aldrich) to study the apoptosis induction pathway 120 
minutes before VP-16 treatment. We administered the specific p38 inhibitor SB203580 (4-(4´-
fluorophenyl)-2-(4´-methylsulfinylphenyl)-5-(4´-pyridyl) imidazole) (20 µM) and a selective inhibitor 
of MAPK/ERK kinase 1 inhibitor PD98059 (2´-amino-3´-methoxyflavone) (Sigma-Aldrich) 2 hours 
before VP-16 to selectively block different signals and measured apoptosis by Annexin V/PI staining. 
Cell lines with empty vector (EV) expression were treated at same drug concentration and during the 
same period. In apoptosis assay cell death of EV was subtracted to ICER expressing cells, whereas in 
western blot the same antibodies were evaluated in the EV protein lysates.  
RNA isolation and SYBR green quantitative real-time RT-PCR (QRT-PCR) assays. Total RNA 
was isolated using TRIzol (Invitrogen) from cell lines after being treated with VP-16 up to 48 hours or 
without being treated. 1 µg of RNA was transcribed using the Superscript II system (Invitrogen-Gibco) 
in 25 µl final volume following manufacturer’s instructions. RQ-PCR was performed with 1 µl cDNA 
in 20 µl using the Sybr Green method (Invitrogen-Gibco) and analyzed on an ABI PRISM 7900HT 
Sequence detection system (Applied Biosystems). 
Western Blot (WB). 20 µg from the total protein fraction (Buffer-Biosource International, CA, USA), 
obtained from HL60+ICER and HL60+EV cell lines, were used to perform protein analyses. Protein 
concentration was determined using the BCA method (Pierce, IL, USA). Samples were subjected to 
10-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to 0.2 µm PVDF 
membranes (GE-healthcare, IL, USA) for immunodetection with a series of antibodies followed by 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit or mouse Ig (Upstate Biotechnology, NY, 
USA). Antibodies used included anti-β-Actin, anti-FLAG and anti-CyclinA1 (Sigma-Aldrich); anti-
BCL-2(C2), anti-DUSP1, anti-DUSP4, anti-IL6 (Santa Cruz Biotechnology, CA, USA); anti-CREB, 
anti-PhosphoCREB, anti-CIP1-p21, anti-Bak (Upstate Biotechnology); anti-CdK2 (78B2), anti-BAX, 
anti-Bcl-xl, anti-Phospho-p44/42 Map kinase (Thr202/Tyr204), anti-Phospho-p38 (Thr180/Tyr182), 
anti-JNK (T183/Y185), anti-AKT (S473), anti PARP, anti-RB (Cell Signaling technology, MA, USA); 
anti-Caspase8 and anti-Caspase3 (Alexis Biochemicals, CA, USA); anti-CyclinE (Oncogene Research 
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Products, MA, USA); anti-CyclinB, anti-CyclinD1 AND ANTI-Kip1-p27 (BD Bioscience, NY, USA). 
The specific bands of target proteins were visualized by enhanced chemiluminescence (ECL advance) 
according to manufacturer’s instructions (GE-Healthcare), and the density of bands were quantified 
using ScionImage software. 
Chromatin immunoprecipitation assay. HL60+ICER and HL60+EV cell lines were processed for 
chromatin immunoprecipitation assay (Upstate Cell Signaling Solutions, VA, USA) following the 
manufacturer's instructions. The immunoprecipitation was performed overnight at 4 °C with rotation 
by using an antibody of interest (CREB, ICER, FLAGM2, RNAPOL) and without antibody selection 
(NoAb) and Immunoglobulin (Ig), as controls. Imput DNA was used as positive control. DNA was 
recovered and used to perform PCR. Agarose gel electrophoresis was performed to observe promoter 
activity. RQ-PCR was also performed by the SYBR Green method for amplification and detection 
(Invitrogen-Gibco) by 7900HT technology (Applied Biosystems) and analyzed by comparative 
threshold cycle (Ct) method. 
Anisomycin treatment. The HL60 parental cell line was treated with anisomycin (Sigma-Aldrich), a 
p38 activator, 2 µM final concentration up to 3 hours. Cell proliferation and apoptosis were measured 
as described above. For rescue experiments, the p38 mitogen-activated protein kinase phosporylation 
inhibitor SB203580 (Sigma-Aldrich) was used at 20µM concentration 2 hours before anisomycin 
exposure or VP-16 treatment. 
siRNA experiments. Exogenous small interfering RNAs (siRNAs) specific for the DUSP1 and 
DUSP4 genes (Dharmacon Industries, Lafayette, CO) were introduced in the HL60 cell line (100 nM 
in 2 ml of medium) by nucleofection. Scramble Sirna (Sc-Sir) were used as negative control. mRNA 
and protein expression were performed to monitor silencing. Apoptosis was measured after VP-16 
treatment. VP-16 1 µM was added after 14 hours of silencing and continuously treated for 24 hours.  
Data analysis. Values are presented as mean ± s.d. Significance between experimental values was 
determined by Student’s unpaired t-test, and one-way ANOVA was used to test differences in repeated 
measures across experiments. p < 0.05 was considered significant. 
 
RESULTS 
ICER expression enhances chemotherapy susceptibility of leukemic cell lines.  
In the present study, we used myeloid leukemic cell lines (HL60, THP-1, ML2,) that were confirmed 
to express CREB at high levels and ICER at nondetectable levels by Pigazzi and colleagues (11). We 
induced ICER transient (t-ICER) expression in these cell lines (Figure 1A) and we treated them with a 
chemotherapeutic agent to investigate the cellular response. We found that exogenous ICER 
expression in HL60, THP-1 and ML2 mediated an increase in apoptosis with respect to EV (whose % 
apoptosis was subtracted from the value presented in the figure) after 24 (13 %, 2.2 % and 2.1 %, n = 
3, p < 0.05 for HL60) and 48 hours (32.2 %, 14 % and 13 % n = 3, p < 0.05 for all cell lines) of VP-16 
treatment (Figure 1B). HL60+ICER was found to be more sensible to VP-16, its lowered cell 
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proliferation was confirmed up to 72 hours of treatment (Figure 1C). The cell morphology showed an 
increased number of apoptotic nuclei after VP-16 treatment in ICER expressing cell lines, confirming 
the HL60 to be more sensitive to the drug (Figure 1C). To evaluate if the increase in apoptosis was due 
exclusively to VP-16, and not to ICER overexpression, two different compounds, Staurosporine 
(stauro) and Doxorubicin (doxo), were also used. The annexin assay showed an increase in apoptosis 
after treatment in all of the cell lines that overexpress ICER. At 24 hours, the increase in apoptosis for 
HL60, THP-1 and ML2 overexpressing ICER was 20.8 %, 8 %, 10.8 % when exposed to doxo; 30 %, 
19.3 %, 10.7 % when exposed to stauro. At 48 hours of treatment 35 %, 8.9 %, 6.4 % for doxo and 41 
%, 40 %, 32 % for stauro. Results are obtained subtracting apoptosis drug mediated in cell line 
transfected with EV. Results showed that all drugs significantly increased cell death in the ICER 
expressing cell lines, demonstrating that ICER role in cell death was regardless of the type of drug 
used (Figure 1D, n = 3, * p < 0.05). 
 
Figure 1. ICER enhances chemotherapy induced cell death. A) Western blot analysis of ICER transient expression (t-
ICER) induced in HL60, THP-1 and ML2 48h post transfection. B) The increase in apoptotic of ICER expressing cell lines 
after VP-16 treatment is shown with respect to cells transfected with EV in the same treatment conditions (its value has been 
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subtracted in the figure, n = 3, * p < 0.05). C) Proliferation of ICER or EV transfected cell lines after VP16 treatment (with 
respect to transfected but untreated cell lines). Treatment and ICER expression conferred the lowest proliferation values after 
48 and 72 h (n = 3). On the right, DAPI nuclear staining after VP-16 treatment in cell lines +ICER reveals chromatin 
condensation, and the number of rounded and fragmented nuclei increased with respect to cells +EV in the same conditions. 
D) Apoptosis of cell lines +EV and +ICER after different drug treatments is shown. Histogram represents the percentages of 
A+/PI+ (to which the value of apoptosis induced by DMSO was subtracted) after 48 h of drug treatments. Apoptosis is 
significantly increased at 24 and 48 h of treatment in cell lines overexpressing ICER (n = 3, * p < 0.05).  
ICER counteracts CREB gene expression.  
By studying the ICER transcriptional repressor activity by RQ-PCR (11), we revealed that the MAP-
phosphatases DUSP1 and DUSP4, the survival molecules ERK1/2 and AKT, as well as controllers of 
the cell cycle progression, Cyclin A1, B1 and D1, were significantly less expressed in HL60+ICER 
cells with respect to HL60+EV cells, or HL60 after VP-16 treatment (Figure 2A, n = 3, * p < 0.05). 
The mRNA repression correlated with protein reduced levels, particularly after 48 hours of VP-16 
treatment, which were not found in the HL60+EV cells treated at the same conditions (Figure 2B). To 
further investigate the role of cyclin down regulation, cell cycle analysis was performed. Results 
revealed mainly an accumulation of sub G0 (apoptotic) HL60+ICER cells after drug treatment. A 
block in the G2-M phase was evidenced mainly after VP-16 and doxo treatment; whereas a rapid 
ongoing to apoptosis mainly after stauro treatment was shown. We documented cell cycle regulators 
p21 and Cdk2 activation up to 24 hours of VP-16 treatment, supporting the G2 block of cell cycle 
progression; their reduction at 48 hours established the maximum effect of treatment linked to higher 
cell death (Figure 2C, n = 2, p < 0.05, ctr = untreated cells).  
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Figure 2. ICER controls gene expression influencing cell cycle and MAP Kinases. A) Histogram shows the relative 
quantitation (RQ) of CREB/ICER target genes of HL60+EV and of HL60+ICER at 48 h of VP-16 treatment compared to the 
untreated HL60+EV cell line used as calibrator (RQ = 1 in the figure, n = 2, * p < 0.05 ). B) Western blot analysis of target 
proteins which were found decreased in HL60+ICER treated with VP16. HL60+EV cell line, treated at same conditions, did 
not show reduction in protein levels. C) Cell cycle analysis of HL60+ICER and HL60+EV cell lines, treated with VP-16, 
doxo, or stauro, were performed after 48h of treatment. Histograms show that HL60+ICER cells treated with drugs present a 
increased sub-G1 phase or block in G2 phase compared to the untreated cells (ctr). Western blot analysis: p21 and Cdk2 are 
activated 24 h post treatment in HL60+ICER, consistently with the block in cell cycle progression and with the reduction of 
cyclins observed in panel 2B.  
 
ICER enhances chemotherapy induced apoptosis by DUSP1/4-p38 pathway.  
The apoptosis previously discussed was confirmed in the HL60+ICER cell line after 24 hours of 
treatment (Figure 3A) by the increase of expression of the following: active caspase-3 (active 
fragments p20, p19 and p17), caspase 8 (active fragments p43/41) and cleaved poly (ADP-ribose) 
polymerase (PARP) (cleaved fragment p89).  
 
 
Figure 3. ICER evokes caspases mediated external apoptosis by p38 pathway. A) Western blot shows the activation 
cleavage mediated of inactive proteins into mature fragments of caspase 3 (p17, p19, p20), caspase 8 (p43, p41) and PARP 
(p89) starting from 24 h of treatment and up to 48 h. B) Western blot analysis showed that apoptosis enforced by ICER was 
found to be caspase-mediated (increase of fragments p43, p41 of caspase 8 and of p89 fragment of PARP). By the use of 
ZVAD as caspase inhibitor, delayed caspase 8 and PARP activation was shown. C) Western blot analysis was conducted on 
the mitochondrial protein fraction (Mt). The presence of BAK confirm that mitochondria are undamaged. The expression of 
antiapoptotic BCL-2 and BCL-XL over the treatment period is not influenced by VP-16 in HL60+ICER cell line. D) DUSP 1 
and 4 are shown to be repressed over treatment (Figure 2B), whereas p38 was kept phosphorylated during the same period of 
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time. The impaired expression of downstream p38 substrates, such as p27, IL6 and RB is documented. Same proteins 
reduction was not observed in HL60+EV treated at same conditions.  
 
We observed that caspase 8 and PARP activation was markedly induced in HL60+ICER with respect 
to the HL60+EV cell line treated in the same conditions. Caspase 8 and PARP activation was 
controlled by the use of the broad inhibitor z-VAD, confirming that ICER evoked caspases to trigger 
apoptosis (Figure 3B). In an attempt to determine the sequence of events involved in ICER mediated 
apoptosis in HL60, we excluded mitochondrial involvement by demonstrating the maintenance of 
BAK, BCL-2, BAX, and BCL-XL protein expression during VP-16 treatment. We checked the 
mitochondrial protein fraction for purity and as loading control, and the presence of BCL-2/BCL-XL 
demonstrated the mitochondrial membrane integrity up to 48 hours (Figure 3C). We then investigated 
the role of the phosphatases DUSP1/4 impaired gene and protein expression mediated by ICER 
repression, and investigated their main target, the proapoptotic p38 protein. Results showed the 
upregulation and maintenance of the phosphorylated form of p38 expression during VP-16 treatment 
of HL60 + ICER. The activation of p38 was confirmed by looking at specific substrates, p27, RB and 
IL6, whose expression was found severely compromised, supporting the observed cell apoptosis 
(Figure 3D). 
ICER activated p38 by repressing DUSP1/4 transcription triggering cell apoptosis in 
HL60 and primary cultures.  
The chromatin at the DUSP1/4 promoter was immunoprecipitated. Pulled-down DNA showed the 
binding of CREB in the HL60+EV cell line partially or totally substituted by ICER when exogenously 
expressed in the HL60+ICER cell line (Figure 4A). Results of RQ-PCR were interpreted by the ∆∆ct 
method considering HL60+EV as calibrator (RQ = 1). The amount of DNA immunoprecipitated by 
CREB was significantly decreased for DUSP1 (RQ = 0.46) and for DUSP4 (RQ = 0.80) in HL60 + 
ICER with respect to HL60 + EV, confirming that ICER might work preferentially on DUSP1 
promoter (p < 0.05) (data not shown). To further emphasize the importance of p38 in regulating stress-
induced AML cell death, HL60 was treated with anisomycin a specific activator of p38. Western blot 
showed that increased phospho-p38 levels contributed to higher apoptosis in the HL60 cell line. By 
using the specific p38 inhibitor SB203580 we prevented apoptosis in the same context (Figure 4B, n = 
3, * p < 0.05).  
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Figure 4. ICER controls DUSP1/4 promoter triggering p38 mediated apoptosis. A) Chromatin immunoprecipitation was 
performed using CREB, ICER or FLAGM2 antibody in both cell lines. FLAG antibody was used to pull down ICER 
exogenous protein, while RNAPOL was used to assess active promoters. Positive control is the imput DNA (ctr+) while 
negative control is obtained without any antibody (NoAb) or using an anti-IgG antibody. B) Western blot shows the increase 
of phosphorylated p38 (p P38) expression after the use of the specific drug anisomycin (aniso). The treatment increases HL60 
apoptosis (A+/PI+) as the consequence of specific p38 induction. By using p38 inhibitor (SB203580), apoptosis was rescued 
(n = 3, *p < 0.05). C) Apoptosis assay (% of annexin V and PI positive cells) was performed in HL60+ICER or +EV cell 
after VP-16 treatment with or without SB203580 pretreatment. Results show a rescue in apoptosis when cells are pretreated 
with SB203. 
 
To prove that the VP-16 enhanced sensitivity induced by ICER expression was mediated by the p38 
pathway, a specific inhibitor of all p38 homologues (p38α, p38β and p38β2), SB203580, was used. 
Apoptosis was found reduced from 13.1 % to 1 % in HL60+ICER 24 hours post treatment and from 
45.7 % to 14.8 % at 48 hours (Figure 4C, n = 3, p < 0.05), suggesting that p38 activation was directly 
involved in the apoptosis mediated by ICER restoration. Apoptosis was rescued by SB20358 also in 
HL60 + EV treated with VP-16, but with lower efficacy (data not shown). 
DUSP1 and DUSP4 silencing phenocopies ICER’s role in parental HL60 cell line.  
The silencing of both DUSP1 and DUSP4 was induced in the HL60 cell line by using small interfering 
RNAs. To evaluate their ability their ability to induce the same effect mediated by ICER restoration in 
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the HL60+ICER cell line. The decreasing expression of DUSP1 and DUSP4 mRNA was measured 
with the ∆∆Ct method considering scramble siRNA as calibrator (RQ = 1). After 16 hours of DUSP1 
silencing, the RQ was strongly decreased (RQ = 0.58), whereas DUSP 4 silencing was inefficient (RQ 
= 0.87). After 30 hours, DUSP1 mRNA was maintained reduced (RQ = 0.65), whereas DUSP4 was 
strongly diminished (RQ = 0.37). Protein levels followed the same trend of mRNA. Protein levels 
followed the same trend of mRNA. DUSP1/4 silencing was documented to increase phospho-p38 
levels (p-p38) after 20 hours; apoptosis was slightly improved as well (data not shown). We then 
treated the DUSP1/4-silenced HL60 cell line with VP-16. Results showed that silenced cells had a 
decreased proliferation and an increased apoptosis with respect to the scRNA used as control. 
Therefore, the parental DUSP1/4-silenced HL60 cell line became more sensitive to the drug treatment, 
as established in the HL60+ICER cell line (Figure 5B, n = 3, * p < 0.05). 
DUSP1 silencing or ICER exogenous expression promote apoptosis in AML primary cultures.  
We silenced DUSP1 in primary BM cultures of AML at diagnosis. In the same cultures, we also 
restored ICER exogenous expression. DUSP1 silencing was more intense after 24 hours (RQ = 0.27) 
(calibrated to Sc-Sir, RQ = 1), with respect to 48 hours (RQ = 0.72). 
 
 
Figure 5. DUSP1/4 silencing phenocopies ICER role in enhancing drug sensitivity. A ) RQ of DUSP1/4 after 16 and 30 h 
of silencing is shown, results are calibrated to Sc-Sir mRNA (RQ = 1) used as control. Western blot shows that silencing of 
DUSP1 and DUSP4 in HL60 cell line decreased their protein expression compared to the scramble siRNA oligonucleotide 
used as control (Sc-Sir) at 20 and 48 h post transfection. An increase in phospho-p38 (p P38) was also found concomitantly 
with silencing of DUSP proteins. B) HL60 cells after 14 h of silencing were treated with VP-16. Their proliferation rate 
decreases over time. The % of apoptosis significantly increases after DUSPs silencing with respect to cells transfected with 
Sc-Sir (sc-Sir value has been subctrated) and treated at the same VP-16 concentration ( n = 3, * p < 0.05 for all time points 
presented). 
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Protein expression was impaired as well. We monitored the effect on p38 levels and found its 
phosphorylation increased, confirming the pathway activation after DUSP1 silencing (Figure 6A). We 
restored ICER expression in the same primary AML cultures by transiently transfecting the pEGFP∆-
N1_FLAG-ICERγ plasmid as well as the Empty Vector as control (EV). DUSP1 mRNA and protein 
expression were found decreased after transfection, confirming that DUSP1 is a downstream target of 
ICER in myeloid leukemia cells. p38 phosphorylation increased (Figure 6B) promoting cell death and 
supporting the same activation pathway in patients of the myeloid cell lines. The scheme in figure 6C 
summarizes a new view of how CREB might influence the survival signaling in myeloid leukemia. 
 
 
Figure 6. DUSP1 silencing or ICER expression promote apoptosis in AML primary cultures. A) Primary cultures were 
used to silence DUSP1. A decrease of DUSP1 mRNA after 24 and 48 h (ScSir used as calibrator, RQ = 1) is shown. DUSP1 
protein levels were lowered and phospho-p38 (P-p38) activated after silencing. B) ICER expression was introduced in 
primary AML bone marrow: DUSP1 mRNA was found reduced (RQ = 0.6 after being calibrated to EV) and protein levels as 
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well. p38 activation was confirmed (P-p38). C) Proposed scheme of the cross-talk between CREB/ICER and the DUSPs/p38 
pathways in leukemic myeloid cells. 
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DISCUSSION 
AML is a heterogeneous tumor, specifically for its clinical outcome and molecular features. 
Although many chromosome abnormalities have been recently characterized, such as gene mutations, 
expression profiles and microRNAs, alternative treatment is needed because resistance to therapy and 
relapse still occur (30). Several approaches are under experimentation to increase cell apoptosis and a 
large number of kinases and phosphatases are under examination in the hematological field. 
Sensitizing cell to drugs could help to improve treatment response, and the characterization of novel 
molecules is urgent (31–33). We previously reported that ICER expression in leukemic cell lines 
induces significant antiproliferative effects (6,11). In this regard, results presented here show that 
restored ICER expression confers an enhanced drug susceptibility to leukemic cells. We described 
DUSP1 expression to be considered as a crucial target in AML treatment response. Focusing on 
DUSP1 and DUSP4 repression as ICER’s main targets, we established their role in p38 activation, and 
elucidated the apoptotic signaling evoked by ICER in myeloid leukemia.  
Multiple pathways might be addressed to be responsive to ICER restoration in leukemia. In 
this article, ICER-dependent regulation of pro- and antiapoptotic genes are demonstrated to enhance 
apoptosis with respect to that observed in leukemia cells without ICER. Cyclins and genes of the 
MAPK signaling pathway were specifically found severely downregulated by both ICER and 
chemotherapy treatment leading myeloid leukemia to a different predisposition to cell death. In 
particular, we found a novel link between ICER and DUSP1/4 phosphatases, whose expression has 
already been reported to be high in different types of tumors, though never previously discussed in the 
leukemia field (34). ICER-mediated transcriptional DUSP1/4 repression was demonstrated to 
contribute to increase p38 phosphorylation, triggering proapoptotic signals. The involvement of p38 in 
mediating apoptosis was confirmed by the use of p38 inhibitor SB203580, which interrupts the 
ongoing process of apoptosis. The induction of DUSP downregulation and p38 activation have been 
demonstrated to activate a cascade of different stimuli (35-37). The downregulation of the cell survival 
signaling of ERK and AKT might concur to enforce the p38-mediated apoptosis (23,38). Furthermore, 
the severe decrease of other downstream factors, such as p27, IL6 and RB, confers the final anti-
survival cellular response. The fact that IL6 and RB transcription depends on CREB activity, whereas 
their phosphorylation on MAPK, confers to these two intricate pathways the ability to converge and 
collaborate for cell growth and AML progression (39,40). The finding of CREB and ICER 
transcriptional regulation of DUSP1/4 reveals a novel role in maintaining the balance between the 
activity of stress and survival kinases, which modulate leukemia cell fate. 
DUSP1 and 4 repression appeared to be the crucial event for drug response of leukemia cell 
lines. The silencing strategy was also used in primary bone marrow cultures of AML at diagnosis to 
assume the same condition of the HL60+ICER cell line. DUSP1/4 down regulation lowered cell 
proliferation, phospho-p38 activation and an increased apoptosis of AML patients phenotyping the 
HL60+ICER cell line behavior. The proposed pathway was confirmed to modulate chemotherapeutic 
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susceptibility of myeloid leukemia. The in vivo strategy was also used to exogenously reintroduce 
ICER expression in primary AML giving the same results as DUSP1 silencing. ICER as controller of 
DUSP1 expression and of p38 pathway activation in AML patients confirmed our hypothesis, opening 
for further investigation in future therapy strategy. 
Taken together, our results describe a novel apoptotic pathway in myeloid leukemia, 
summarized as a working model in Figure 6C: in HL60, CREB overexpression maintains high ERK 
levels, which takes ICER to degradation (11); DUSP1 and 4 dephosphorylate p38, supporting survival 
and leukemia growth. In the HL60+ICER cell line, ICER is highly expressed. It decreases CREB 
expression and promotes gene repression, in particular of DUSP1/4, which in turn allows p38 to 
remain phosphorylated and to trigger apoptosis. Lowered CREB levels and high p38 levels maintain 
ERK downregulated, preventing ICER degradation and contributing to tumor suppression (41,42). The 
identification of this pathway, confirmed in AML patients at diagnosis, offers novel targets to be 
considered in leukemia treatment. In particular, we support the idea that DUSP1 inhibition by ICER is 
a good strategy to sensitize cancer cells to conventional chemotherapy and to inhibit tumor growth. 
With regards to leukemogenesis, blocking CREB or inducing ICER might be further considered as 
phenomena involved in malignant transformation. 
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ABSTRACT  
Background. MiR-34b downregulation in acute myeloid leukemia was previously shown to 
induce CREB overexpression thereby causing leukemia proliferation in vitro and in vivo. The role of 
miR-34b and CREB in patients with myeloid malignancies were never evaluated. 
Design and Methods. We examined miR-34b expression and the methylation status of its 
promoter in cells from patients diagnosed with myeloid malignancies. We used gene expression 
profile to identify signatures of myeloid transformation. We established miR-34b suppressor ability 
and CREB oncogenic potential in primary bone marrow cell cultures and in vivo. 
Results. MiR-34b was found to be upregulated in pediatric patients with juvenile 
myelomonocytic leukemia (n=17) and myelodysplastic syndromes (n=28), but was downregulated in 
acute myeloid leukemia patients at diagnosis (n=112). Our results showed that hypermethylation of the 
miR-34b promoter occurred in 66% of acute myeloid leukemia explaining the low miR-34b levels and 
CREB overexpression, whereas preleukemic myelodysplastic syndromes and juvenile 
myelomonocytic leukemia patients was not associated with hypermethylation or CREB 
overexpression. In paired samples of myelodysplastic syndromes and subsequent acute myeloid 
leukemia from the same patients, we confirmed miR-34b promoter hypermethylation at leukemia 
onset, with 103 CREB target genes differentially expressed between the two disease stages. This 
subset of CREB targets was confirmed to associate with high risk myelodysplastic syndromes in a 
separate cohort of patients (n=20). 78 of these 103 CREB targets were also differentially expressed 
between healthy samples (n=11) and de novo acute myeloid leukemia (n=72). Further, low miR-34b 
and high CREB expression levels induced aberrant myelopoiesis through CREB-dependent pathways 
in vitro and in vivo.  
Conclusions. We suggest that miR-34b controls CREB expression and contributes to myeloid 
transformation from both healthy bone marrow and myelodysplastic syndromes. We identified a 
subset of CREB target genes that represents a novel transcriptional network that may control myeloid 
transformation. 
 
INTRODUCTION 
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression at 
a post-transcriptional level. MiRNA expression patterns are regulated during development and 
differentiation of the hematopoietic system and have an important role in cell proliferation, apoptosis, 
differentiation and even tumorigenesis (1). In acute leukemia, various miRNAs and their functions 
have been intensively studied, but the precise mechanisms that control their expression and critical 
targets are largely unknown for the majority of aberrantly expressed miRNAs (2). The discovery of 
miRNAs as a new class of post-transcriptional regulators that act via interactions with their target 
messenger RNAs has revealed an important pathway for controlling gene expression (3, 4).  
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Previously, we reported that miR-34b regulates CREB expression levels in myeloid cell lines 
by directly binding to its 3’untranslated region (UTR) (5). MiR-34b/c has been implicated in colon (6), 
ovarian (7) and oral oncogenesis (8). Here, we further studied the role of miR-34b in the pathogenesis 
of myeloid malignancies. One mechanism by which miRNAs are frequently silenced in human tumors 
is aberrant hypermethylation of CpG islands that encompass or lie adjacent to their genes or by histone 
modifications (9, 10). DNA methylation is in fact increasingly recognized as important in the 
regulation of normal and tumor cells (11, 12), the latter being characterized by specific 
hypermethylation of CpG islands in the promoters of tumor suppressor genes, resulting in 
transcriptional repression and gene inactivation (1, 3, 4, 9-12).  
We identified hypermethylation as a cause of decreased miR-34b levels in leukemia cell lines, 
which in turn directly controls the expression of the proto-oncogene cAMP-response-element-binding 
protein (CREB)(5). CREB is known to regulate a wide range of cellular processes such as growth, 
proliferation, differentiation and apoptosis. Furthermore, it plays a crucial role in normal (13) and 
neoplastic hematopoiesis (14-17). CREB knockdown decreases proliferation and survival of myeloid 
progenitor cells and regulates the differentiation of committed progenitors (13). CREB is 
overexpressed in bone marrow from AML patients and increases AML cell proliferation in vitro and 
in vivo, through upregulation of specific target genes (13, 15). CREB overexpressing transgenic mice 
develop a myeloproliferative neoplasm with splenomegaly but not AML, highlighting a causative role 
for CREB in myeloid cell transformation (13). However, the consequences of abnormal expression of 
both CREB and miR-34b in AML are not well defined, and the role of both CREB and miR-34b in 
transition from MDS to AML has not been examined.  
In this report, we studied a cohort of patients with JMML and MDS as well as de novo AML 
at diagnosis to study CREB and miR-34b. We investigated the role of their abnormal expression in the 
development of a malignant phenotype using in vitro and in vivo assays. Our results suggest that miR-
34b promoter hypermethylation leads to CREB derepression and MDS evolution into AML through 
upregulation of a subset of CREB target genes. 
 
DESIGN AND METHODS 
Patients. We studied bone marrow (BM) samples from 112 patients with AML at diagnosis enrolled 
in the AIEOP-2002 AML pediatric protocol. The cohort of 28 pediatric MDS samples was composed 
of 6 refractory cytopenia of childhood (RCC), 22 refractory anemia with excess blasts (RAEB) 
according to the MDS classification proposed for pediatric patients (ages 0-18, age mean 10.26 ± 
4.43). Seventeen pediatric patients (ages 0-18, age mean 2.51 ± 3.76) affected by juvenile 
myelomonocytic leukemia (JMML) according to differential diagnostic criteria, as previously 
published, were also included in the study. The enrollment criteria of the study are described in 
Supplementary Online Design and methods (18, 19). DNA and RNA were extracted and analyzed for 
methylation of miR-34b promoter, and for miR-34b levels. CD19-CD3- from 17 pediatric healthy BM 
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(HL-BM) (ages 0-18, age mean 11.86 ± 4.84) were used as control samples in the assessment of miR-
34b expression in AMLs.  
RNA isolation and SYBR Green real-time-PCR (RQ-PCR) assays. Total RNA was isolated using 
Trizol (Invitrogen). One microgram (µg) of RNA was reverse-transcribed into cDNA using the 
SuperScript II (Invitrogen) according to the manufacturer’s instructions. RQ-PCR was performed with 
SYBR Green method (Invitrogen) and analyzed on an ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems) (20). Experiments were carried out in triplicate and gene expression, 
relative to GUS, was calculated by the comparative ∆∆Ct method (21).  
RNA isolation and Real Time PCR (RQ-PCR) for miRNA analysis. Ten nanograms (ng) of total 
RNA were used as starting material for the stem-loop RQ-PCR method to detect the expression level 
of mature miR-34b (Applied Biosystems). All PCRs were run in triplicate and gene expression relative 
to RNU6B, was calculated by the comparative ∆∆Ct method (21).  
Methylation analysis. One µg of genomic DNA extracted from pediatric samples of 112 AML, 28 
MDS, 17 JMML, 3 HL-BM, from sorted CD34+ of MDS and HL-BM samples according to the 
manufacturer’s instructions (Gentra Autopure LS, Qiagen) was treated with sodium bisulfite using EZ 
DNA Methylation-Gold Kit (ZYMO RESEARCH). A methylation-specific (MS) and 
unmethylation-specific (UMS) PCR reaction to detect the methylation status of miR-34b promoter was 
performed as previously described by Lujambo et al. (22). PCR amplicon obtained by MS-PCR was 
sequenced by an ABI PRISMTM310 Genetic Analyser sequencer (Applied Biosystems). (see 
Supplementary Online Design and Methods). 
Gene expression analysis. Seventy-two bone marrow samples from patients with de novo AML at 
diagnosis, 24 MDS at diagnosis, 4 AML that evolved from MDS, and 11 healthy bone marrows were 
subjected to gene expression analysis. This series of de novo AML patients encompasses 16 patients 
with Core Binding factor aberrations, 23 MLL-rearranged positive patients, 30 patients with normal 
karyotype and 3 with complex karyotype. Promyelocytic AML with t(15;17) were a priori excluded 
from this series as they constitute an independent group. RNA quality was assessed on an Agilent2100 
Bioanalyzer (Agilent Technologies). The GeneChip Human Genome U133 Plus 2.0 was used for the 
microarray experiments as previously described (23-26). (Supplementary Online Design and 
Methods).  
Gene Set Enrichment Analysis (GSEA). Gene expression profiles obtained from 19 out of 72 AML 
patients at diagnosis were analyzed by using GSEA (http://www.broadinstitute.org/gsea/index.jsp) 
(see Supplementary Online Design and Methods).  
Principal Component Analysis (PCA). We studied gene expression for an independent cohort of 20 
samples from MDS patients at diagnosis, selecting the top 103 genes among CREB targets. PCA was 
performed using Partek Genomic Suite Software. 
Primary cell culture and transfection. Primary cell cultures were obtained from BM from healthy 
donors. CD34+ sorted cells from human fetal liver were also used (27). Cell transfection was 
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performed using a Nucleofector (Amaxa Biosystems) according to the manufacturer’s guidelines and 
efficiency was up to 40%. Cell cycle analysis and colony assays were performed (see Supplementary 
Online Design and Methods). 
Constructs. pEGFP-N1-∆GFP-CREB plasmid was obtained by cloning between the NotI and EcoRI 
cloning site a full length cDNA for CREB into the pEGFP-N1 vector (Invitrogen). Lentiviral 
constructs were constructed as previously described by Gentner et al.(28,29) (see Supplementary 
Online Design and Methods).  
Western blot analysis (WB). WB were performed as previously described (30). Antibodies used were 
anti-Actin (Sigma-Aldrich), anti-PU.1, anti-GATA1, anti-MEIS1/2, anti-cMET, anti-cMYB (Santa 
Cruz Biotechnology), anti-cMYC, anti-CDK6 (GeneTex), anti-CREB, anti-P-CREB, the horseradish 
peroxidase–conjugated secondary antibody was goat anti-rabbit or mouse IgG (Upstate 
Biotechnology).  
Flank injection xenograft experiments in NOD-SCID IL-2receptor gamma null (NSG) mice. Ten 
NSG mice between 6 to 8 weeks of age were injected subcutaneously with 5×106 HL60-miR-
34b/LUC (or EV/LUC as a control) or K562-miR-34b/LUC (or EV/LUC as a control) cells. All mice 
were euthanized when tumors reached a volume of 1.5cm3. The mice were treated according to the 
NIH Guidelines for Animal Care and as approved by the UCLA Institutional Animal Care and Use 
Committee. 
Xenograft experiments by bioluminescence Imaging in NSG mice. Ten mice were injected with 
5×106 HL60-34b/LUC (or EV/LUC as a control) cells through the tail vein. Mice were imaged 
(IVIS100 bioluminescence/optical imaging system Xenogen) every week to monitor tumor 
engraftment and growth since 21 day post transplant. Three mg/mouse of D-Luciferin (Xenogen) in 
PBS was injected intraperitoneally 15 minutes before measurement (Relative Intensity units (RIU) = 
photons/sec/cm2). General anesthesia was induced with isoflurane. RIU for regions of interest were 
measured in triplicate and averaged.  
Data analysis. Statistical analyses were performed by using Mann-Whitney or unpaired two-tailed t 
test. A p value of < 0.05 was considered significant. 
 
RESULTS 
MiR-34b promoter is hypermethylated in AML.  
MiR-34b expression was already reported to be downregulated in 78 patients with AML at diagnosis 
(15). We enlarged this cohort of patients to 112, confirming its downregulation with respect to HL-
BM (RQAML= 0.178, RQHL-BM= 1). We previously correlated this decrease in miR-34b expression with 
promoter hypermethylation in leukemic cell lines (15). Here, we investigated miR-34b promoter 
hypermethylation directly in 112 AML patients. MS-PCR revealed 74/112 (66%) AML patients 
demonstrated miR-34b promoter hypermethylation (Figure 1A). We sequenced the amplicons and 
confirmed the presence of CpG islands in patients with miR-34b promoter hypermethylation, whereas 
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the TG nucleotides at same position were found in unmethylated cases after bisulfite treatment. The 74 
patients with hypermethylation of miR-34b promoter had significantly lower miR-34b expression and 
higher CREB protein levels, compared to the 38 patients without hypermethylation of miR-34b 
promoter where miR-34b was highly expressed (RQMeth= 0.075, RQUnmeth= 0.373, p< 0.05) and CREB 
protein was undetectable by Western blot analysis. Moreover, 19 AML patients were analyzed for 
gene expression profile using GSEA. Results showed that patients with hypermethylation of miR-34b 
promoter, and therefore miR-34b lowered levels, had a positive enrichment of genes predicted to be 
miR-34b targets (Figure 1S). These results suggested that hypermethylation of miR-34b promoter is a 
common feature in pediatric AML. Then, we studied the Event free Survival (EFS) of this AML 
patient cohort (74 AML patients with miR-34b promoter hypermethylation vs 38 patients not 
methylated at same promoter). There was a trend towards lower overall survival of AML patients with 
methylated miR-34b promoter (69 % at 4y) compared to patients with unmethylated promoter (61 % 
at 4y), but these results did not reach statistical significance (p = 0.34). Still, the methylation of miR-
34b promoter might have negative prognostic significance in AML. There was not a significant 
independent correlation among clinical and biological parameters with the methylation of miR-34b 
promoter (Figure 2S). These findings suggest that cells from a large group of AML patients (66%) 
have miR-34b promoter hypermethylation (15), suggesting that this may be contributing to 
leukemogenesis.  
Mir-34b expression is higher in MDS or JMML since miR-34b promoter is not 
hypermethylated.  
We examined miR-34b expression in other rare pediatric hematopoietic disorders such as MDS (22 
RAEB, 6 RCC) and 17 JMML, which can sometimes transform into AML. MiR-34b expression was 
higher in patients with RAEB (RQmean= 5.74), RCC (RQmean= 8.79) and JMML (RQmean= 8.86) 
compared to AML at diagnosis (RQ= 1). We then investigated miR-34b promoter methylation status 
in this cohort of myeloid malignancies. MS-PCR revealed that miR-34b promoter was never 
methylated in this cohort of samples, and sequencing always showed TG nucleotides at the CpG 
islands after bisulfite treatment (Figure 1C). However, since the expression of miR-34b is 
heterogeneous and some patients have low miR-34b expression, a nested PCR was performed to 
increase the sensitivity of the target amplicon detection (sensibility up to 10-6 as calculated with serial 
dilution of MS-PCR positive AML samples). These results confirmed the absence of methylation in all 
the MDS and JMML samples at diagnosis. Moreover, we sorted CD34+ hematopoietic cells from HL-
BM or MDS patient samples to verify if the methylation of miR-34b promoter was found only in stem 
cells and therefore not detected in the whole bone marrow of patients. Neither HL-BM nor MDS 
sorted CD34+ cells showed hypermethylation of miR-34b promoter (Figure 1C). Furthermore, CREB 
expression was undetectable in MDS samples (Figure 1D).  
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Figure 1. Methylation status of miR-34b promoter in AML, MDS or JMML patients. A. Methylation Specific PCR 
(MS-PCR) analysis of the miR-34b/c promoter in a representative set of AML patients samples is shown. HL60 cell line and 
healthy bone marrow samples (HL-BM) were used as positive and negative controls respectively. Direct sequencing of the 
miR-34b/c promoter amplicon after bisulfite treatment confirmed the methylation of GC nucleotides in the miR-34b 
promoter of patients. B. RQ-PCR analysis of this group of patients with the hypermethylation of miR-34b promoter (Meth, 
RQ=0.075) and without the hypermethylation of the promoter (Un-Meth, RQ=0.373, * p<0.05). CREB expression by WB in 
AML patients with or without methylated promoter. . C. MS-PCR analysis of the methylation of the miR-34b/c promote CpG 
island in a representative set of MDS patient samples. HL60 cell line and healthy bone marrow samples (HL-BM) were used 
as positive and negative controls, respectively. Direct sequencing of the miR-34b promoter amplicon confirmed the 
unmethylation of GpC islands shown as T nucleotides after bisulfite treatment. HL-BM and MDS CD34+ sorted cells did not 
show, as well, a methylation specific band. D. WB of a representative cohort of MDS patients shows a non-detectable levels 
of CREB expression in MDS samples. HL60 cells were used as positive controls 
 
MiR-34b promoter hypermethylation occurs during transformation from MDS to AML.  
MDS is a disease known to evolve to AML in 30% of cases. We examined miR-34b expression in 3 
patients where paired samples were available at diagnosis of MDS and at the time of progression to 
AML. MiR-34b expression decreased following transformation into AML (RQmeanMDS= 0.61 vs 
RQmeanAML= 0.26). MS-PCR on the same paired disease samples revealed hypermethylation of 
miR-34b promoter exclusively in the AML specimens (Figure 2A). We then studied the gene 
expression profiling (GEP) in paired RNA samples at both MDS and AML diagnosis that were 
available for 4 patients. Using a supervised analysis we found a set of genes (175, see Supplementary 
table 1S) that were significantly (p< 0.05) differentially expressed between the two diseases. To 
interrogate the transcriptional programs associated with the aberrant expression of miR-34b and 
CREB, we intersected our gene expression data with CREB-target genes identified by performing 
ChIP on Chip analysis in human tissue (table S4 at http://natural.salk.edu/CREB/) (31). This analysis 
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revealed that 103/175(59%) genes differentially expressed were CREB target genes. We used the 103 
CREB target genes as a new subset to perform hierarchical clustering analysis. Results revealed that 
CREB targets were able to distinguish the MDS from their own AML evolution (Figure 2C). Then, by 
PCA analysis we validated the 103 CREB target genes in an independent cohort of 20 MDS patients at 
diagnosis. This analysis showed that two distinct groups of MDS were generated. One included four 
high risk MDS patients (who are known to be evolved into AML with a median interval between 
diagnosis and evolution = 225 days, range 59-714 days; mean age difference between the two groups 
it is not statistically significant) and the other included low risk MDS patients (that were not evolved 
at the time of the study from 3-10 years from diagnosis) (26) (Figure 2D). Therefore, differential 
expression of CREB target genes marks MDS, high risk MDS (MDS that evolved) and AML, 
supporting the role of miR-34b and CREB in the myeloid transformation process. To identify the 
mechanism of miR-34b downregulation, we performed MS-PCR on the four evolved MDS, finding 
that miR-34b promoter hypermethylation became evident at the onset of AML, supporting the idea 
that promoter hypermethylation occurred during the transition from MDS to AML. 
 
Figure 2. Characterization of MDS patients and their evolution into AML. A. MS-PCR analysis of the miR-34b 
promoter in 3 MDS patients evolved to AML. Methylation of promoter is present just at the onset of AML. Fold reduction of 
miR-34b expression for each patients samples was 15.9, 1.16, 2.9. B. Venn diagram shows the overlap (103 genes) between 
genes differentially expressed by GEP and human CREB targets (by ChIP-chip database, (29)) among the MDS and 
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evolution into AML. C. Hierarchical clustering analysis of 4 patient pairs at diagnosis of MDS and their evolution into AML 
using the 103 differentially expressed CREB-target genes divided the MDS from their evolution into two separate clusters. D. 
Principal Component Analysis using 103 CREB target genes that distinguishes MDS from their evolution to AML in an 
independent cohort of 20 MDS patients. Patients are divided between those known to be evolved (red), and those not evolved 
(blue). In black there is the centroid of the two groups of patients. 
 
CREB overexpression in HL-BM induces dismyelopoiesis through its targets upregulation.  
To study the effect of CREB overexpression in myeloid transformation, we transiently transfected 
healthy bone marrow cultures with a full-length plasmid containing CREB cDNA. We confirmed 
increased protein levels post CREB transfection (Figure 3A). Cell cycle analysis showed a slight 
increase in S phase cells after CREB overexpression (Figure 3B) (cell apoptosis was similar in cells 
transfected with CREB or empty vector, data not shown). The clonogenic growth of bone marrow 
cells overexpressing CREB was enhanced as measured by methylcellulose colony assays (Figure 3C). 
By FACS analysis we identified increased numbers of erythroid precursors (CD45 negative), an 
increased number of cells positive for erythroid and megakaryocyte markers (CD36, Glycophorin A, 
and CD61), and for granulocyte/monocyte marker (CD15) in CREB overexpressing cells (Figure 3D, 
ns). We investigated CREB targets of the myeloid lineage expression, and found GATA-1 and PU.1 
proteins being upregulated by Western blot analysis (32, 33). MEIS-1, a known CREB target gene in 
AML, was also found increased (34, 35) (Figure 3E). We performed RQ-PCR for previously 
confirmed CREB targets (20) finding that most of them were increased in normal bone marrow 
cultures with enforced CREB expression (Figure 3F). Next, we investigated the expression of a series 
of CREB target genes that were extrapolated from the analysis of MDS evolved into AML (see 
supplementary table 1S). These novel CREB target genes were upregulated after CREB exogenous 
transfection (Figure 3G). To better dissect the mechanism of transformation, we analyzed the gene 
expression profile of 72 AML at diagnosis versus 11 healthy volunteers. We found 15597 present calls 
by Affymetrix parameters expressed in all the 11 HL-BM analyzed and intersected this result to the 
12407 genes present in CREB-database (that we previously used in our gene expression analysis (31) . 
We found 3281/12407 CREB target genes expressed in HL-BM, that represent the 25% of expressed 
genes in normal bone marrow. When we compared gene expression from HL-BM and de novo AML, 
we found 2618 genes differentially expressed (FDR< 0.05) between the two groups, and among them 
1195/2618 (46%) were CREB targets (previously found by human Chip-chip analysis) (31). The 
differences highlighted by these probe sets are not due to age difference of HL-BM and AML, since 
their mean is not statistically different. We therefore defined a crucial subset of CREB targets that are 
expressed at AML onset versus HL-BM. We intersected these data with the gene expression data 
regarding CREB genes in the transition of MDS to AML, in the above section, and found that 78 out 
of 103 genes (76%) were common between the two data sets (Figure 3H, See supplementary table 1S). 
Furthermore, if one examines all genes (CREB targets and non-targets) that are significantly 
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differentially expressed and in common between the two processes, CREB targets are enriched 
(78/131 CREB targets (60%)) compared with non-targets (53/131,40%).  
 
 
Figure 3. CREB overexpression in normal bone marrow cultures. Healthy bone marrow transiently transfected with a 
CREB overexpressing vector (CREB) or a control (EV). A. WB 16h and 24h post transfection: induced CREB protein 
expression is shown in CREB transfected cells. B. Cell cycle analysis in transfected healthy bone marrow showed an 
increased S-phase in CREB transfected HL-BM (n = 2). C. Colonies growth in methocult were counted after 14 days of 
culture and histograms represent the number of colony formed by CREB expressing cells (white bar) with respect to those 
formed by cells transfected with control vector (EV = 100%, black bar,* p< 0.05). D. FACS analysis of myeloid and 
erythroid markers (CD15, 61, CD45-, CD36, Glycoforin) in healthy primary culture transfected with CREB (white bar) 
compared to EV (black bar) showed an increase in all myeloid markers. E. WB of PU.1, GATA-1 and MEIS-1 16 and 30h 
post transfection showed an increase in expression of those protein after CREB exogenous expression in healthy bone 
marrow after 30h. Densitometry measured the expression levels normalized to total amount of Actin. F. Expression of CREB 
target genes 24h post transfection was RQ BCL2= 2.20, CyA1= 1.04, CyB1= 1.93, CyD1= 2.4, NFKBp50= 1.11, p21= 1.26, 
STAT3= 1.63. Each gene quantification has been normalized to the RQ of HL-BM transfected with EV (RQ = 1) (n= 3). G. 
Expression of genes extrapolated in Figure 2B (see Supplementary table 1S).was RQ ADAM10= 1.82, CDK6= 2.54, 
HOXA7= 1.26, LTS2= 2.75, PKACB= 1.97. Each gene quantification has been normalized to the RQ of HL-BM transfected 
with EV (RQ= 1) (n= 3). H. Venn diagram representation shows the overlap between genes differentially expressed between 
the MDS and their evolution, genes differentially expressed between AML and HLBM and CREB targets by ChIP-chip 
database (29). 
 
MiR-34b inhibition phenocopies CREB uperegulation in healthy fetal liver (FL) cells.  
Since decreased expression of miR-34b leads to CREB overexpression, we measured miR-34b levels 
in whole HL-BM (RQmean=13.66, n=17), in CD34+ sorted HL-BM cells (RQmean= 9.08, n= 3) and 
CD34+ sorted FL cells (RQmean= 43.14, n= 6). Our results demonstrated that miR-34b expression 
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was higher in healthy hematopoietic tissues than in bone marrow from patients with AML (n= 3, p< 
0.05). To study the role of miR-34b in human fetal liver cells, we knocked down miR-34b using a 
lentiviral sponge vector containing four in tandem miR-34b target sequences (28, 29). Infected cells 
were sorted and analyzed. MiR-34b expression decreased by 75% compared to negative control (RQ= 
0.25), whereas CREB levels were increased (RQ= 4.48) in addition to CREB target genes known to 
influence myeloid leukemia (Figure 4A). We next analyzed cell morphology and phenotype of miR-
34b knockdown human fetal liver cells. MGG staining revealed a larger number of myeloid precursors 
and differentiated cells (examples are highlighted in the 60X square), indicating an aberrant expansion 
of the myeloid compartment (Figure 4B). A difference in the percentage of myeloid markers by flow 
cytometry was also documented (Figure 4C). Since decrease of miR-34b expression can affect CREB 
expression, we examined the clonogenic properties in methylcellulose colony assays. Enhanced 
colony formation in the miR-34b knockdown human fetal liver cells was observed compared to the 
scrambled miR-target (miR-Neg, Figure 4D). Therefore, miR-34b is critical for normal hematopoietic 
proliferation and differentiation.  
 
Figure 4. MiR-34b knockdown in CD34+ fetal liver cells. A.Expression of known CREB targets was BCL2= 1.44, CyA1= 
2.09, CyB1= 1.51, CyD1= 0.54, NFKBp50= 1.37, STAT3= 13.5. Each gene quantification has been normalized to the RQ of 
fetal liver transduced with EV (RQ= 1) (n= 3). B. Representative microscope field of a May-Grünwald-Giemsa (MGG) 
staining (20X) of fetal liver cell with a knock down in miR-34b shows an increase in all the myeloid populations compared to 
EV. Example of myeloid cells not found in the controls are reported in the enlargement (60X). C. By FACS analysis we 
showed an increase in myeloid markers (CD33 and CD15) in cells of fetal liver transduced with miR-TARGET (white bar) 
compared to control (black bar) (CD33= 35.4% vs 18%, CD15= 3.3% vs 2.5%, * p< 0.05). D. Histogram represents the 2-
fold increase in number of colony formed after knockdown of miR-34b (white bar) with respect to those formed by cells 
transfected with miR-NEG (miR-NEG= 100%, black bar,* p< 0.05). 
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MiR-34b is an AML tumor suppressor in vivo.  
To confirm the hypothesis that miR-34b is a tumor suppressor in AML, we transduced HL60 and 
K562 leukemic cell lines with lentivirus for miR-34b or miR-Neg (RQmiR-34b up to 10-3 fold 
increase). MiR-34b overexpression decreases CREB expression as shown by Western blot analysis 
(Figure 5A). The introduction of miR-34b in K562 did not affect cell proliferation in vitro (data not 
shown). We next injected HL-60 and K562 cells into NSG mice and monitored tumor formation. We 
observed that cells injected into the flank of NSG mice with K562+miR-34b developed smaller tumors 
(0.68g) 21 days post-injection compared to K562 + empty vector (1.18g) (Figure 5B, mice n= 10 in 
each cohort, p< 0.05). The same result was observed for HL60+miR-34b (0.79g) compared to 
HL60+empty vector (1.39g) (Figure 5C, mice n=10 in each cohort, p< 0.05). Furthermore, 5x106 
HL60+miR-34b or HL60+empty vector cells were injected into the tail veins of 5 mice per group to 
analyze the effect of miR-34b overexpression in leukemia cell engraftment and progression. Results 
showed a decreased engraftment and disease progression in mice injected with HL60+miR-34b 
compared to the empty vector controls monitored by acquiring in vivo bioluminescence 2 and 3 weeks 
after inoculation. After two weeks, mice injected with cell lines+miR-34b did not show a significant 
difference in tumor size compared to cell lines+empty vector. However, after 3 weeks, the mice 
injected with cell lines+miR-34b had a significant decrease in tumor progression due to miR-34b 
overexpression (p< 0.01, Figure 5C). Other miR-34b targets, such as C-MYB, CDK6 and MET (22, 
36), were not found significantly reduced in the transplanted cell lines (data not shown). These 
experiments suggest that miR-34b is a tumor suppressor in AML principally by inhibiting CREB 
expression. 
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Figure 5. MiR-34b suppresses CREB expression and AML progression in primary cultures and in vivo. A. Western 
blot analysis confirmed the reduction of CREB protein levels in leukemic cell lines (K562 and HL60) after infection with 
Fugw-miR-34b with respect to empty vector (EV). Densitometric analysis: HL-60 = 0.7±0.15 vs. 1, and K562 = 0.22±0.24 
vs. 1, n = 3, p < 0.05. B. Tumor weight of the xenograft model obtained with a flank injection of K562 or HL60 leukemic cell 
lines overexpressing miR-34b in NSG mice was reduced in comparison to EV injected cells. Error bars represent standard 
deviation. * p< 0.05. C. In vivo imaging with IVIS 100 bioluminescence/optical imaging system (Xenogen) of mice tail vein 
injected with 5x106 HL60-34b or EV transduced cells 2 or 3 weeks post injection. The histogram shows a decrease in the 
Relative Intensity Units (RIU) of mice injected with leukemic cell line overexpressing miR-34b compared to those injected 
with the control cell line (n= 5 each group, p= 0.01).  
 
DISCUSSION 
In this paper, we show that AML patients have decreased miR-34b expression through aberrant 
hypermethylation of the miR-34b promoter CpG island. Interestingly, hypermethylation of miR-34b 
promoter was completely absent in primary samples of HL-BM as well as in MDS or JMML patients. 
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We considered the childhood myelodysplastic syndromes because of their propensity to evolve into 
acute myeloid leukemia in approximately 30-40% of cases (19, 37, 38). Primary bone marrow samples 
from MDS and its corresponding, transformed AML allowed us to show that cells acquired miR-34b 
promoter hypermethylation during the evolution to AML. Epigenetic modification of miR-34b 
promoter results in aberrant CREB levels. We previously showed a direct interaction of miR-34b with 
the CREB 3'-untranslated region using a reporter assay, with the subsequent reduction of the CREB 
protein levels in vitro. We also documented that miR-34b overexpression caused cell cycle 
abnormalities, reduced colony assay growth, and altered CREB target gene expression in leukemic cell 
lines (5). Here, we demonstrate a direct link between miR-34b and CREB expression in pediatric 
myeloid malignancies. By using an integrative bioinformatic approach, we identified a subset of genes 
that could potentially mediate this transformation. We extrapolated a series of genes that were able to 
significantly cluster MDS from their paired AML samples. CREB target genes represented 59% of 
differently expressed genes, and were also able to distinguish high risk MDS from the low risk MDS, 
therefore being a marker of disease evolution into AML. The differentially expressed genes that were 
non-CREB targets, did not predict correctly all the four cases of MDS that evolved into AML, 
supporting the idea that CREB targets play a main role in triggering the disease evolution. To further 
support the hypothesis that CREB, through its targets, contributes to myeloid transformation, we used 
de novo AML and healthy bone marrows and performed gene expression analysis intersecting those 
results with the CREB target genes database. Fifty percent of CREB target genes, which are two-fold 
more than typical CREB targets expressed in normal bone marrow, were found to be differentially 
expressed between healthy bone marrow and bone marrow from AML patients, suggesting that CREB 
overexpression activates a pathway that is involved in the pathogenesis of AML de novo. We 
intersected gene expression profiles of MDS evolved into AML and healthy bone marrow into de novo 
AML, extrapolating 78/103 genes in common with known CREB target genes. A relative enrichment 
of CREB targets with respect to non-targets supports our hypothesis that CREB controls a key 
pathway involved in the myeloid transformation. These results suggest that during transformation 
from normal bone marrow as well as from MDS, CREB target genes may represent a common 
involved pathway. Among the targets there were several genes already known to play a role in tumor 
process, such as RAB7L1, CDK6, HOXA7 and PKACβ, the catalytic subunit beta of the protein 
kinase A which posphorylates CREB on Ser133, enhancing its transcriptional activation. We propose 
that CREB is one of the regulators of the transcriptional program associated with myeloid leukemia, 
and moreover is critical to the pathogenesis of myeloid transformation. The fact that CREB driven 
expression profile “signature” is also found in MDS samples that are prone to evolve into AML even 
if miR-34b promoter is not methylated, might be due to PKACβ expression. This gene encodes for the 
catalytic subunit beta of protein kinase A, that leads to CREB phosphorylation, and consequently 
CREB transcriptional activation. We found that PKACβ expression increased from HL-BM, to MDS 
to AML. In this scenario, we suppose that it triggers CREB activation during high risk MDS, this 
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condition is then stabilized and worsened with the hypermethylation of miR-34b promoter at the onset 
of leukemia leading to AML. Previous results documented that PKACβ is activated in proliferating 
cells also in a cAMP independent mechanism, leading to cell transformation (39), supporting its role 
in our model. Nevertheless, our data suggest that future studies may shed light to this mechanism.  
 Finally, we examined the role of miR-34b inhibition and CREB overexpression in vitro and 
in vivo. The inhibition of miR-34b levels in healthy bone marrow and fetal liver cells enhances cell 
proliferation and clonogenic potential, leading to aberrant myelopoiesis. Our results showed that miR-
34b rescue had a minor effect on cell growth in leukemic cell lines. However, miR34b overexpression 
suppressed tumor growth in vivo, suggesting that the microenvironment may play a role in the tumor 
suppressive activity of miR-34b. Moreover, in an attempt to demonstrate that miR-34b acts solely 
through CREB, we rescued CREB expression on K562 stably expressing miR-34b. Our data did not 
show a significant increase in cell growth after CREB rescue, and this may be due to the fact that 
leukemia cell line have a high proliferative rate and multiple mutations affecting various signaling 
pathways. In vivo rescue experiments are needed in the future to prove this hypothesis, and to 
eventually identify other miR-34b targets. 
These data implicate CREB overexpression, together with the alteration of its target genes, 
acting as a driving force in AML transformation from both healthy bone marrow and MDS. This work 
highlights the oncogenic circuitry that is fed by the hypermethylation of miR-34b, increased CREB 
levels, and a potential downstream mechanism involved in the pathogenesis of AML transformation. 
Furthermore, the CREB subset of genes may be considered a novel transcriptional network that 
controls the leukemia phenotype, which can guide further functional studies and therapeutic 
opportunities, and represents a novel approach to evaluate risk stratification of MDS patients.  
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ABSTRACT 
Leukemias are the most common form of pediatric cancers, and whereas Acute Lymphoblastic 
Leukemia treatment has made significant progresses over the past decades reaching up to 86 % of survival, 
Acute Myeloid Leukemia (AML) survival reaches the 60 % of patients, and 30 % of AML patients relapse 
within 2 years from remission. The cAMP responsive element binding protein (CREB) has been found 
overexpressed in pediatric AML patients, correlating with an increased risk of relapse, but the pathogenesis 
of CREB’s role in AML is still debated. To better understand CREB’s mechanism of transformation and its 
possible therapeutic targeting, we developed a zebrafish in vivo model that overexpress human CREB in 
myeloid precursors. Results showed that CREB-overexpression led to hematopoiesis perturbation from 
larvae until adultness, with an altered CREB target gene expression, which conferred an enhanced cell cycle 
progression to myeloid cells. After 6 months of CREB enforced expression, zebrafish kidney marrow 
showed dysmyelopoiesis, with increased myelocytes and monocytes counts. At the age of 9 months, CREB-
overexpressing zebrafish developed a sick phenotype with abdominal and dorsal enlargement that 
morphologically resembled an abdominal mass formed by clonal cells with infiltrating capability. The mass 
cells were found to originate from the cells overexpressing human CREB, to rapidly proliferate and to 
migrate into gills, adipose tissue and muscles. Mass cell morphology was similar to that of kidney marrow 
with a complete lack of myelocytes, and a preponderance of monocytes, confirming a myeloproliferative 
disease. The long latency of disease onset suggests that additional events may occur. Finally, by using this 
zebrafish model, CREB molecular pathways associated to transformation may be identified, and subsequent 
genetic screens to identify novel therapeutic targets will be pursued.  
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INTRODUCTION 
Leukemias are defined as a group of disorders characterized by the uncontrolled proliferation and the 
block of the differentiation of hematopoietic cells. Such malignancies arise from abnormal precursors cells 
that have acquired a series of mutation, or have lost their physiological regulating mechanism [1]. Overall 
leukemia is the most common form of pediatric cancer (30%), nowadays Acute Lymphoblastic Leukemia 
(ALL) and Acute Myeloblastic Leukemia (AML) can be cured in 86% and 63% of patients respectively, but 
challenges remain [2]. The causes that leads to leukemia development in pediatric patients are largely 
unknown, as still debated are the causes to treatment failure and relapse. Risk adapted therapy has been the 
cornerstone of ALL therapy, whereas improvements in AML therapy have been limited being generally 
associated with escalation of induction therapies, improvements of intensive supportive care measures, and 
extreme intensification of chemotherapy finalized to bone marrow transplantation. Nowadays, up to 25% of 
AML pediatric patients experienced relapse within 1 years of remission with a cure rate survival less than 
30%. This may be due to the inability of drugs to effectively eradicate the leukemic stem cells, or to target 
the cooperating mutations that occur to transform cells. For leukemia, several genetic lesions of transcription 
factors, tyrosine kinases, and transcriptional regulators that derive from genetic lesions or from aberrant 
chromosomal translocations, have been established. The cAMP response element-binding protein (CREB) is 
a 43-kDa nuclear transcription factor of the basic leucine zipper (bZIP) family. It recognizes the conserved 
cAMP-responsive elements (CRE) at gene promoters, leading to the transcription of its target genes in 
response to various stimuli that activate protein kinases, mainly protein kinase A (PKA), that activates its 
transcriptional activity phosphorylating CREB at its Ser133 residue [3, 4]. Through activation of its target 
genes, it controls crucial physiological function as cell growth, survival and proliferation [5]. CREB has been 
found overexpressed in adult and pediatric AML, and it has been established a proto-oncogene in AML since 
it leads to abnormal cell proliferation, cell cycle progression and higher clonogenic potential in vitro and in 
vivo. CREB overexpressing transgenic mice have been shown to develop myeloproliferative disorder 
between the age of 14 and 20 months [6]. Its overexpression has also been associated with high risk AML 
patients [6, 7]. Nevertheless the mechanism underlying CREB-mediated hematopoietic disorders remains 
unknown. Here, we take advantages of zebrafish (Danio rerio) in vivo model to depict the processes altered 
by CREB aberrant expression. Zebrafish model is useful to study human cancer with a genetic approach, 
such as mutagenesis and screening, and its optical transparency during embryonic stages allows the 
monitoring of biological processes throughout development [8, 9]. Furthermore, zebrafish are well-
established useful for studying hematopoiesis: erythroid, myeloid and lymphoid lineages have been 
characterized, and the molecular pathways governing their development are largely conserved between 
mammals and zebrafish [8]. Moreover, several human oncogenes involved in leukemogenesis have been 
shown to disrupt normal hematopoiesis in zebrafish, and to resemble human hematological disease [10-14]. 
Zebrafish Creb1 is located at chromosome 1. It encodes a 311 amino acids protein, sharing 88.7 % identity 
with human CREB, conserving the activation domain (kinase inducible domain (KID), DNA-binding (DBD) 
and leucine zipper dimerization domains), that implies functional conservation [15]. We established a 
zebrafish model with human CREB enforced expression under the control of pu.1 promoter to investigate its 
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role in hematopoiesis and in leukemogenesis, Pu.1 is an Ets family transcription factor that plays a restrictive 
role in hematopoietic cell lineage, both myeloid and lymphoid. During hematopoiesis, pu.1 is upregulated 
with myeloid commitment, being strongly expressed in myeloid precursor cells [16]. We assessed embryos 
and larvae for defects in primitive and definitive hematopoiesis, respectively, and monitored CREB 
overexpressing zebrafish for incidence of disease. Perturbations in the hematopoietic compartment and on 
CREB target genes were seeked. Here, we revealed that CREB overexpression in zebrafish triggered 
dismyelopoiesis that led to an abnormal phenotype in adult zebrafish, with clear features of a myeloid 
disorder. This model emerged to be useful to study the events driven by CREB to enhance cell 
transformation and for further therapeutic screening.  
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MATERIALS AND METHODS 
Plasmid construction. The human CREB1 was amplified using F: AGTCGAATTCAATGACCATGG and 
R AGTCCTGCAGTTTCCTCATTT primers, then cloned in frame to eGPF into pME-eGFP (383, Tol2kit) 
[17]between, between EcoRI and PstI restriction sites.  
The p5’-228-pu.1 promoter plasmid was obtained by excising the 9kb pu.1 promoter sequence from zpu.1p-
GFP plasmid using SalI and SacII restriction enzyme (NEB), and by cloning it into p5E MCS (228) [16, 17].   
The Invitrogen MultiSite Gateway Technology was used to generate the plasmids for zebrafish embryos 
injection. The Gateway strategy allows modular assembly of promoter, coding sequence and 3’tag in a Tol2 
transposon backbone. Transposon elements enable random plasmid integration into genome, through 
transposase enzymatic reaction. The plasmids were recombinated through LR reaction (Gateway 
Technology) according to manufacturer’s recommendation (Invitrogen), using LR plus clonase enzyme and 
performing the reaction for 16 h at 25°C. After LR reactions, 2 µl of the sample was transformed into TOP 
10 bacteria. Clones were selected on carbenicillin plates and screened by PCR, miniprep and DNA 
sequencing. Entry and destination vectors used from Tol2kit were: 299 (p5E-bactin2), 228 (p5E-MCS), 383 
(pME-EGFP), 302 (p3E-polyA), 394 (pDestTol2pA2) [17]. Plasmid for RNA probes synthesis were obtained 
by PCR fragments generated from a pool of cDNAs from zebrafish embryos at different stages (at 24 and at 
48 hpf) and cloned into pCRII-TOPO (Invitrogen, Carlsbad, CA). Probes for rb1 and jun were designed from 
the published NCBI sequence (NM_001077780.1) (F: cgtgtctcctctgaaaagca; R: ctgcccaggaagaacgtaa) and 
from NCBI sequence of reference was NM_199987.1 (F: caccgctctctcctatcgac; R:tgaggtgctcagaaaacaaaca), 
respectively. Pu.1, gata.1 and mpo plasmids used to synthesize riboprobes were kindly provided from 
Professor Felix CA, bcl2 from Dr. Forrester AM [14]; p21 from Dr. Chen J [18]; ccnD1 from Dr. Bessa J 
[19]. 
Zebrafish maintenance and microinjection. Embryos were grown at 28.5 C, and developmental staging of 
injected zebrafish embryos was determined by hours post fertilization (hpf), according to Kimmel et al. [20]. 
At established time points single cell plasmid injection was performed. Purified vectors were diluted at a 
final concentration of 30 ng/µl, and trasposase mRNA at a final concentration of 25 ng/µl in Danieau 
solution [58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, and 5 mM HEPES (pH 7.6)], 
with 10% phenol red. Trasposase mRNA synthesis was performed using mMESSAGE mMACHINE T7/SP6 
kit (Ambion, Austin, TX), using pCS-TP plasmid, kindly provided by Dr. Koichi Kawasakami.  
The plasmids and the trasposase mRNA (25 ng/µl) was diluited in Danieau solution with 10% phenol red. 
Microinjections of 2 nl of solution were performed into the yolk of fertilized one-cell stage embryos. 
Fluorescence was monitored on a Nikon SMZ1500 zoom stereomicroscope (Nikon Instruments Inc). 
Whole-mount in situ hybridization (WISH). Digoxogenin (DIG) -labelled antisense zebrafish RNA probes 
were synthesized according to manufacturers’ instruction. Briefly, plasmids were linearized with NotI or 
BamHI restriction enzyme (NEB) and all antisense riboprobe were synthesized using DIG RNA Labeling Kit 
(SP6/T7) (Roche). Whole-mount in situ hybridization (WISH) for mRNA expression were performed as 
previously published [21]. Embryos were fixed in 4% paraformaldehyde (PFA) and the DIG probes were 
detected using anti-DIG-alkaline phosphatase (AP) and NBT/BCIP. After in situ hybridization, embryos 
 70 
were put in 4% paraformaldehyde in PBS and mounted in 85% glycerol/PBS. Embryos were visualized and 
imaged with Nikon SMZ1500 zoom stereomicroscope (Nikon Instruments Inc). 
Luciferase assay. For luciferase activity detection, pDest-βactin:eGFP_CREB-polyA or pDest-βactin:eGFP-
polyA together with pAd C6-6xCRE_luciferase plasmids were injected at equimolar ratios of 20 ng/µl. 
Renilla plasmid was used at 1:10 ratio (2 ng/µl). After 24 and 48 h of injection proteins were extracted and 
analyzed by Dual Luciferase Assay System (Promega).  
RNA extraction and SYBR Green quantitative real-time reverse transcription-PCR assays. Total RNA 
from zebrafish embryos at 24 and 48 hpf was extracted using Trizol (Invitrogen). RNA (1 µg) was 
transcribed using the SuperScript II system (Invitrogen) following the manufacturer's instructions. RQ-PCR 
was performed with 1 µL cDNA in 20 µL using the SYBR Green method (Invitrogen) and analyzed on an 
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Expression values were normalised 
to zf β-actin and expressed as fold change relative to the control injected zebrafish group.  
 
bactin F TGCTCCCCGAGCTGTCTT jun R CAGACATCAAGCCCCTGAAGTT 
bactin R ACCAACCATGACACCCTGATG dusp1 F CGAGGCCATCGAATTTATTG 
scl F GGGAGCGCGGATATAAAAGG dusp1 R CGCATCAGATAAGCCAGACA 
scl R GAGGCAGTGGCAAGGGAAT dusp4 F GAGGACATCAGCTCCTGGTT 
gata-1 F CAGTTCAGCAGCGCTCTATTCA dusp4 R TGGAATCCTTGACGGAGTCTAT 
gata-1 R AGCCTCAGGTGGCGAAAGT rb1 F CCCACAGAAGAAAGAGCTGAA 
pu.1 F AGAGAGGGTAACCTGGACTG rb1 R GGATCCTTGTCCTTGTGTCG 
pu.1 R AAGTCCACTGGATGAATGTG stat3 F TCTCCCGGTGGTGGTCAT 
l-plastin F GAAGCTCTGATCGCTCTGCT stat3 R AATTCACGTTCTTGGGATGGTT 
l-plastin R GTTGTTGATTTTGGGGCATC jak3 F AACTGGCCTGTGCTCTTAACTT 
Runx1 F CCGACTCCCGGCAGATG jak3 R TCTTTGCACAAATATTCCCATGT 
Runx1 R AGATCGGGCCCAGATATGG gata2 F CCACTGCAAGAATGGACGAA 
c-myb F CAGTTTGGGACACCGTGATG gata2 R GCCAAGCTTCCCCGAAGA 
c-myb R GGAGAGATGTGACAGTGGTTTGC ccnA1 F GACGGCTGCAATACTCCTG 
jun F CTGCCAGCTCATGTTGACACA ccnA1 R CGTGATGTAGACAAACTCATCCA 
 
Table 1. RQ-PCR primer sequences. 
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FACS cell sorting of kidney tissue or abdominal mass. Kidney or abdominal mass isolated from 
wild-type fish or leukemic fish were homogenized in protease solution (Collagenase/Dispase 1:200, 
DNAse 1:1000, MgCl2 1:1000 in phosphate-buffered saline) at 37°C for 30 minutes and manually 
dissected. The whole suspension was filtered through a 45 µm cell strainer. before being analyzed at 
BD Facs Aria III (Becton Dickinson), as previously described [10]. 
Hisytology, immunohistochemistry and cytology. Whole adult zebrafish were euthanized with 2 
mg/ml MS-222 at pH 7 (Tricaine; Sigma-Aldrich), fixed in 10% neutral buffered formalin, embedded 
in paraffin, and 5 µm serial sections were obtained. Hematoxylin and eosin (H/E) staining, and 
immunohistochemical analyses were performed. For this purpose, sections were re-hydrated and then 
antigen retrieval was performed by incubation with citrate buffer 0.01 M pH6 at 95 °C for 20 min. For 
immunohistochemistry, slides were incubated with 1:400 dilution anti-GFP (B-2) Ab (Santa Cruz 
Biotechnology), 1:500 dilution anti-CREB (Millipore), 1:500 dilution anti-PCNA (FL-261) Ab (Santa 
Cruz Biotechnology) for 1 hour and then developed with the DAKO Envision Detection Kit. Kidney 
or abdominal mass isolated from zebrafish were imprinted on glass, and stained with Wright-Giemsa 
and Alpha-naphtyl acetate esterase (ANAE) with standard procedures. Images were captured on a 
Nikon SMZ1500 zoom stereomicroscope (Nikon Instruments Inc), or on a ViCo Nikon eclipse 80i 
microscope.  
Data analysis. Values are presented as mean ± standard deviation (sd). Significance between 
experimental values was determined by Student's unpaired t-test, and Fisher's exact test. P < 0.05 (*) 
was considered significant.  
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RESULTS 
CREB is induced in myeloid cell lineage and works as a transcription factor 
To investigate the oncogenic properties of CREB, we created a CREB-overexpressing in vivo model 
by injecting eGFP_CREB fusion gene under the control of pu.1 promoter into 1-cell stage fertilized 
embryos. CREB exogenous expression was monitored by eGFP expression. The fluorescent signal 
was observed from 20 hpf in the anterior lateral mesoderm (ALM) and intermediate cell mass (ICM), 
both sites of primitive myelopoiesis. eGFP expression was found also in muscle, indicating ectopic 
pu.1 promoter expression as previously observed (figure 1) [16]. 
 
Figure 1. pu.1:eGFP_CREB injected embryos expressed CREB gene under the control of the 9.1 kb zebrafish pu.1 
promoter. At 24 hpf eGFP_CREB expressing cells were detected in ALM (left picture, white arrowhead), and in ICM (right 
picture, white arrowhead). Ectopic eGFP expression in musculature were detected as well (right picture, yellow arrow). 0.7 x 
original magnification 
 
Then, we aimed to confirm CREB activity as transcription factor. In human, it recognizes the cAMP 
response elements (CREs) consensus regions and activates the transcription of a large number of 
genes. To verify if its activity is maintained in zebrafish, we co-injected pu.1:eGFP-CREB and a 
reporter plasmid, made up of 6xCRE repeats upstream to a red fluorescent mCherry protein. At 24 hpf 
we observed a co-expression of eGFP and mCherry in CREB-injected embryos indicating that CREB 
recognized the consensus regions, and activated the transcription of mCherry gene. In the control 
zebrafish injected with the reporter plasmid and the empty vector pu.1:eGFP we did not observe the 
co-localization of signals (figure 2).  
Furthermore, to confirm the transcriptional activity of CREB in zebrafish embryos, we co-injected a 
ubiquitous plasmid βactin:eGFP-CREB together with a reporter construct containing 6xCRE repeats 
located upstream to a luciferase reporter gene. Luciferase activity was measured 26 hpf, and was found 
significantly increased of 2.7 fold in CREB-injected zebrafish respect to control-injected zebrafish 
(mean luciferase activity βact:eGFP = 7.5, sd = 4.6, n = 3; mean luciferase activity βact:eGFP_CREB 
= 20.2, sd = 5.2, n = 5; p= 0.01). At 48 hpf the luciferase activity was also found increased of 2.7 fold 
in CREB-injected zebrafish respect to control-injected zebrafish, but results were not significant 
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probably due to the relative luciferase plasmid dilution during time following the high cell 
proliferation in early embriogenesis (mean luciferase activity βact:eGFP = 7.5, sd = 5.4, n = 4; mean 
luciferase activity βact:eGFP_CREB = 20.6, sd = 12.4, n = 3; p = 0.1). These results indicated that 
exogenous CREB recognized the same CRE consensus regions, and therefore may increase the 
transcription of zebrafish target genes.  
 
 
Figure 2. Increased trascriptional activity in CREB-injected zebrafish. A) Co-expression of eGFP and mCherry signal 
was detected in pu.1:eGFP_CREB and 6xCRE_mCherry co-injected embryos (right panel), but not in pu.1:eGFP and 
6xCRE_mCherry co-injected embryos (left panel). 0.7 x original magnification B) An increased luciferase activity was 
observed in βactin:eGFP-CREB-injected zebrafish compared to βactin:eGFP-injected zebrafish at 26 hpf (left panel, p = 
0.01), and at 48 hpf (right panel, p = 0.1). * p < 0.05 
 
CREB overexpression perturbs gene expression of primitive and definitive zebrafish 
hematopoiesis 
To study the effects exerted by CREB overexpression in myeloid cells, we focus on the expression of 
specific genes by RQ-PCR on the whole embryos till 48 hpf. We selected genes associated with early 
primitive hematopoietic precursors (scl), erythroid (gata1), early and late myelomonocytic lineages 
(pu.1 and lcp). Genes that regulate hematopoietic stem cells (HSCs) onset during definitive 
hematopoiesis such as runx1 and c-myb were also studied. In CREB-overexpressing zebrafish, genes 
involved in primitive hematopoiesis were found lightly upregulated at 24 hpf (scl fold change:1.4 ± 
0.3, p = 0.2, gata1 fold change: 1.1 ± 0.3, p = 0.6; pu.1 fold change: 1.1± 0.4, p = 0.7; lcp fold change: 
1.2 ± 0.3, p = 0.4) as well as genes that regulates definitive hematopoiesis (runx1 fold change: 1.6 ± 
0.4, p = 0.1; c-myb fold change: 1.4 ± 0.2, p = 0.1). At 48 hpf genes expressed by hematopoietic 
precursors were found still upregulated (scl fold change: 1.1 ± 0.1, p = 0.5; gata1 fold change: 1.3 ± 
0.4, p = 0.4; pu.1 fold change: 1.7 ± 0.9, p = 0.4), as well as gene of myelomonocitic lineage (lcp fold 
change: 1.1 ± 0.1, p = 0.1). Viceversa, runx1 was found significantly decreased (fold change: 0.9 ± 
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0.01, p = 0.006), while c-myb remained upregulated (fold change: 1.6 ± 0.4, p = 0.1) (Figure 3A). 
These results indicated a broad aberrant gene expression of all the hematopoietic cell lineages 
analyzed. Next, we investigated the expression of a series of previously confirmed CREB targets 
found to be aberrantly expressed in human bone marrow cells by CREB enforced expression [22]. 
Results revelaed that jun expression was not affected (fold change at 24 hpf: 1.1 ± 0.1, p = 0.4; at 48 
hpf: 1.1 ± 0.4, p = 0.8), whereas genes encoding dusp and jak3 were not differently expressed with 
respect to control (dusp1 fold change at 24 hpf: 0.9 ± 0.03, p = 0.02; at 48 hpf: 1 ± 0.1, p = 0.9; dusp4 
fold changes at 24 hpf: 0.8 ±0.1, p = 0.1; 48 hpf: 0.8 ± 0.3, p = 0.4; jak3 at 24 hpf: 0.8 ± 0.4, p = 0.5; 
48 hpf: 0.7 ± 0.04, p = 0.09). In contrast rb1, stat3, gata2 and cyclin A1 expression were found 
increased (rb1 fold change:1.4 ± 0.04 at 24 hpf, p = 0.005, 1.4 ± 0.1 at 48 hpf , p = 0.07; stat3 fold 
change at 24 hpf: 2.1 ± 0.8, p = 0.2; at 48 hpf: 2.1 ± 1.1, p = 0.3; gata2 fold change at 24 hpf: 1.7 ± 
0.2, p = 0.04, at 48 hpf: 1.8 ±1.3, p = 0.4; cyclinA1 fold change at 24 hpf: 4 ± 1.6, p = 0.1; at 48 hpf: 
2.5 ± 1.6, p =0., figure 3B). These results revealed an aberrant upregulation of main oncogenic 
transcription and cell cycle factors.  
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Figure 3. Gene expression analysis investigated by RQ-PCR of CREB-overexpressing zebrafish compare to control-
injected zebrafish (used as calibrator, RQ = 1). A) Fold changes of genes involved in zebrafish primitive hematopoiesis 
(scl, gata1, pu.1, lcp) and genes that mark HSCs during zebrafish definitive hematopoiesis (runx1, c-myb), at 24 hpf and 48 
hpf. B) Fold changes of known human CREB target genes that are important in different cell pathways: MAPK signaling 
pathway (jun, dusp1, dusp4), cell-cycle apoptosis pathway (rb1), stat3, jak3, gata1, ccna1. * p < 0.05. 
 
In order to monitor CREB effects on spatial and temporal foci of hematopoiesis, we performed RNA 
whole mount in situ hybridization (WISH) on CREB-overexpressing zebrafish. At 20 hpf 100% (n = 
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30) of CREB-overexpressing embryos displayed high pu.1 positive cell number in ALM, whereas 17 
out of 20 control zebrafish showed the same expression (85%, p = 0.05); 100% of CREB-
overexpressing embryos displayed a strong gata1 expression in ICM (n = 33), compared to 78% of 
control zebrafish injected with the empty vector (n = 23, p = 0.009, Figure 4A). At 24 hpf, the 
expression of myeloperoxidase, feature of more mature myeloid granulocytes, was seen in 36% (n = 
25) of CREB-overexpressing embryos compared to 4% of the control zebrafish (N = 26, p = 0.005, 
Figure 4B, left panel). These data suggested that CREB exogenous expression altered the early 
hematopoietic compartment development in zebrafish, by influencing both the myeloid and erythroid 
lineages commitment during primitive hematopoiesis, even if this perturbation was not sufficient to 
induce embryogenic defect or altered larvae phenotype. 
We then analyzed the first wave of definitive hematopoiesis, which occurs between 1 to 2 day post 
fertilization (dpf), when erythromyeloid progenitors (EMPs) have been described to be in the posterior 
blood island (PBI) [23]. We looked at gata1 and pu.1 expression, finding that gata1 signal in 40% (n = 
10) of CREB-overexpressing zebrafish at 30 hpf was increased, whereas none of control zebrafish 
showed this strong gata1 expression (n = 5, p = 0.2, Figure 4B, right panel). These results were in 
agreement with our previous findings in humans, where CREB-induced overexpression in healthy 
bone marrow cells caused an increased number of cells positive for erythroid and 
granulocyte/monocyte markers [24]. 
 
Figure 4. WISH for primitive hematopoietic genes. A) CREB-overexpressing larvae at 20 hpf showed that there are 
increased number of pu.1 positive cells: 100 % (n = 30) of CREB-overexpressing embryos compared to 85 % (n = 20) of 
controls (P= 0.05); significant gata1 increase was found: strong signal in 100 % (n = 33) of CREB-overexpressing embryos 
compared to 78 % (n = 23) of control zebrafish (p = 0.009, right panel). B) mpo expression at 24hpf showed a significant 
augmented positive cell number: 36 % of CREB overexpressing zebrafish (n = 25) compared to 4 % (n = 26) of control 
embryos (p = 0.005, left panel). WISH for gata1 expression in PBI during transient hematopoiesis at 30hpf showed an 
increased gata1 signal in 40% (n = 10) of CREB-overexpressing embryos compared to none of controls (n = 5. p = 0.2, right 
panel).* p < 0.05. 
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We then performed WISH using specific RNA probes against CREB target genes to evaluate effects 
on its downstream pathways. At 24 hpf in ALM, CREB-overexpressing zebrafish showed an increased 
expression of bcl2 in 17% of embryos (n = 12) compared to 0% of controls (n = 12, p = 0.5, figure 5A, 
left panel), and of jun in 58% of embryos (n = 24) compared to 6% (n = 17) of controls (p < 0.001, 
figure 5A, right panel). Moreover, when CREB target genes involved in cell cycle control have been 
considered, we found a detectable expression of p21 in 24% ( n = 21) of CREB-overexpressing 
embryos, compared to 59% (n = 17) of controls, resulting in a significant decrease of p21 expression 
in CREB-overexpressing zebrafish (p = 0.046, figure 5B, left panel), and an detectable ccnd1 
expression in 42% (n = 19) of CREB-overexpressing embryos, with respect to 25% (n = 20) of 
controls (p = 0.3, figure 5B, right panel). These results suggested a dysregulation of cell cycle towards 
an enhanced cell proliferation.  
 
 
Figure 5. WISH for CREB target genes. A) WISH for bcl2 and jun performed on CREB-overexpressing zebrafish and 
control ones at 24hpf shows increased bcl2 signal in 17 % (n = 12) of CREB-overexpressing embryos compared to none (n = 
12) of control ones (p = 0.5, left panel), and significant increased jun signal: 58 % (n = 24) of CREB-overexpressing embryos 
compared to 6 % (n = 17) of control ones showed strong jun signal. (p < 0.001, right panel). B) WISH for genes involved in 
cell cycle regulation displays that expression of p21, that negatively control G1/S transition, is significantly decreased: its 
expression is found in 24 % (n = 21) of CREB-overexpressing zebrafish with respect to 59 % (n = 17) of control ones (p = 
0.046,left panel); ccnd1 expression is detected in 42 % (n = 19) of CREB-overexpressing zebrafish compared to 25 % (n = 
20) of control embryos (p = 0.3, right panel).* p < 0.05. 
 
CREB alters myelopoiesis during zebrafish development 
To observe hematopoietic perturbation during zebrafish development we monitored hematopoietic 
organs of injected zebrafish during time. First group of 3 CREB-overexpressing and 3 control 
zebrafish at the age of 3 months were sacrificed. Sagittal sections of paraffined CREB zebrafish did 
not show morphological abnormalities in kidney marrow characters, neither in other tissues such as 
muscles, adipose tissue, gills and skin (Figure 6).  
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Figure 6. H&E staining of sagittal slides of pu.1:eGFP_CREB and pu.1:eGFP control zebrafish 3 months aged. A) 
Pu.1:eGFP-injected zebrafish showed normal phenotype at the main organs. B) pu.1:eGFP_CREB-injected zebrafish showed 
no evident abnormalities in organs size nor tissues. Legend: A: adipose tissue; K: kidney; M: muscle; S: skin. 
 
The second group was sacrificed at the age of 6 months, and kidney dissected. We performed slides 
and stained for cell morphology analysis. As described in figure 7, pu.1:eGFP_CREB # 12 zebrafish 
showed significant impairment in number of lymphocytes (22 ± 2%, compared to 41 ± 11 % in control 
zebrafish, p = 0.04) and a significant increase in number of monocytes (22 ± 1% compared to 14 ± 2% 
in control zebrafish, p < 0.01), whereas no significant differences in number of myelocytes (35 ± 6% 
compared to 26 ± 9% in control zebrafish, p =0.22) and erythroblasts (22 ± 10% compared to 19 ± 4% 
in control zebrafish, p = 0.65) were found. Pu.1:eGFP_CREB # 16 zebrafish showed a significant 
difference in number of erythroblasts (9 ± 4% compared to 19 ± 4% in control zebrafish, p = 0.04), but 
no significant variation in number of lymphocytes (39 ± 7% compared to 41 ± 11% of control 
zebrafish, p = 0.80), myelocytes count (32 ± 9% compared to 26 ± 9% of control zebrafish, p = 0.46) 
and monocytes count (19 ± 7% compared to 14 ± 2% of control zebrafish, p = 0.30) was found (Figure 
7 A, B). 
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Figure 7. Blood cell count rating of kidney imprints of 6 months aged CREB-overexpressing or control zebrafish. A) 
Cell counts with standard deviation (n counts = 3). B) Histogram representation of the hematopoietic lineage rate. Bars 
represent the mean of 3 independent measurement for each sample. * means statistical significant = p < 0.05. C) Wright-
Giemsa staining of representative slides. Legend: white arrow: lymphocytes; green arrow: myelocytes; red arrow: 
erythroblasts; yellow arrow: monocytes. 60x original magnification. Pu.1:eGFP control zebrafish, with normal kidney 
population of lymphocytes, myelocytes, erythroblasts and monocytes. D) Pu.1:eGFP_CREB # 12 showed an unbalanced 
blood cell count with higher monocytes rate at the expense of lymphoid lineage E) Pu.1:eGFP_CREB # 16 showed an 
unbalanced blood cell count with an impairment of erythroblasts and a predominance of monocytes and myelocytes.  
 
Then, we sacrificed three adult zebrafish 8 months post CREB injection. Sorting of dissociated cells of 
kidney from control zebrafish revealed that there were 4 distinct population of cells with different 
physical parameters. In contrast, the same analysis performed in CREB-overexpressing zebrafish 
showed the absence of the myeloid precursors compartment, with an increase of 
granulocytes/monocytes rate, confirming an impaired lineage commitment. We considered to exclude 
mature erythocytes and dead cells, and try to measure the hematopoietic lineages distribution after 
CREB expression. In particular, pu.1:eGFP_CREB # 18 zebrafish showed that most of cells (74%) 
were matured into granulocyte/monocytes population. Lymphocytes were similar (28% instead of 
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22%, figure 8 A, B). pu.1:eGFP_CREB # 20 zebrafish showed the same phenotype, with the 69% of 
mature granulocyte/monocytes population, whereas lymphocytes rate hasn’t found affected (31 % 
instead of 22 %, figure 8 A, C). These data suggested an aberrant maturation of cells into myeloid 
lineage. Kidney imprints of CREB-injected zebrafish and same age controls were analyzed for blood 
cell counts. As illustrated in figure 8, pu.1:eGFP_CREB # 18 zebrafish showed a decrease of 
lymphocytes (25 ± 6%, compared to 43 ± 1% in control zebrafish, p = 0.01); an increase in number of 
myelocytes (30 ± 8% compared to 20 ± 1% in control zebrafish, p =0.10), in erythroblasts (29 ± 9% 
compared to 12 ± 4% in control zebrafish, p = 0.08) even if statistical significance was not reached, 
and no significant variation in monocytes was found (21 ± 4% compared to 25 ± 4% in control 
zebrafish, p = 0.29). The same phenomenon of dysmyelopoiesis was observed in the 
pu.1:eGFP_CREB # 20 zebrafish: a significant lowered number of lymphocytes (29 ± 5% compared to 
43 ± 1% of control zebrafish, p = 0.01), an increase in erythroblasts (22 ± 11% compared to 12 ± 4% 
in control zebrafish, p = 0.21), and no relevant differences in myelocytes (19 ± 6% compared to 20 ± 
1% of control zebrafish, p = 0.79), or monocytes (30 ± 9% compared to 25 ± 4% of control zebrafish, 
p = 0.43, Figure 8 D, E).  
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Figure 8. Blood cell analysis of 8 months aged CREB-overexpressing or control zebrafish kidney. A) Sorting plot of 
dissociated cells of kidney from control zebrafish B) and C) Sorting plot of dissociated cells of kidney from CREB-
overexpressing embryos D) table of percentage of the diverse hematopoietic lineage cell number ( n = 3). E) Histogram 
representation of the different hematopoietic lineages. Bars represents the mean of 3 independent measurement for each 
sample. * means statistical significance = p < 0.05 Representative pictures of Wright-Giemsa staining of 8 months aged 
zebrafish kidney imprints. F) pu.1:eGFP control zebrafish with normal rate of lymphocytes, myelocytes, erythroblasts and 
monocytes. G and H) pu.1:eGFP_CREB # 18 and pu.1:eGFP_CREB # 20 showed an increase in myeloid, eryhroid and 
monocytic lineages at the expense of a lowered lymphocytes number. Legend: white arrow: lymphocytes; green arrow: 
myelocytes; red arrow: erythroblasts; yellow arrow: monocytes. 60x original magnification. 
 
Furthermore, the third zebrafish pu.1:eGFP_CREB # 19 sacrificed at 8 months from injection, 
revealed an acute lymphoblastic leukemia with a monomorphous cell population infiltration (Figure 9 
C). Sorting of dissociated cells from kidney showed 90% of lymphocytes, whereas in the control 
zebrafish all the hematologic lineages were represented (22% lymphocytes, 35 % 
granulocytes/monocytes and 43 % myeloid precursors populations, figure 9 A, B).  
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Figure 9. Blood cell analysis of 8 months aged CREB-overexpressing or control zebrafish kidney. A) Sorting plot of 
dissociated cells of kidney from control zebrafish B) Sorting plot of dissociated cells of kidney from pu.1:eGFP_CREB # 19 
embryo. C) Representative pictures of Wright-Giemsa staining of 8 months aged zebrafish kidney imprints. Kidney showed 
lymphoblasts totality, with the complete absence of the rest of hematopoietic cell lineages. 60x magnification. 
 
Giving that zebrafish were developing a hematopoietic disorder,, we considered to monitor our adult 
injected zebrafish cohort more frequently. We sacrificed four zebrafish at 9 month of age. Kidney 
imprints from CREB-overexpressing zebrafish and controls were analyzed for blood cell counts. The 
pu.1:eGFP_CREB # 21 presented a significant increase in monocytes rate (28 ± 2%, compared to 22 ± 
3% in control zebrafish, p = 0.04), as well as in erythroblasts (32 ± 7% compared to 18 ± 6% in 
control zebrafish, p = 0.06), whereas myelocytes and lymphocytes number was slightly decreased (20 
± 4% compared to 33 ± 15% in control zebrafish, p = 0.22 and 20 ± 3% compared to 27 ± 12% in 
control zebrafish, p =0.38, respectively). Pu.1:eGFP_CREB # 24 zebrafish showed a significative 
increase in number of monocytes (28 ± 1% compared to 22 ± 3% in control zebrafish, p = 0.03), but 
not significant dissimilarities in number of lymphocytes (21 ± 4% compared to 27 ± 12% in control 
zebrafish, p =0.46), myelocytes (30 ± 1% compared to 33 ± 15% in control zebrafish, p = 0.75) and 
erythroblasts (22 ± 1% compared to 18 ± 6% in control zebrafish, p = 0.32). Pu.1:eGFP_CREB # 25 
and Pu.1:eGFP_CREB # 26 zebrafish showed no significant differences in any hematopoietic lineages 
even if a trend towards an increase in myeloid cell amount was observed (# 25 = lymphocytes 13 ± 3% 
compared to 27 ± 12% in control zebrafish, p =0.12; myelocytes 43 ± 9% compared to 33 ± 15% in 
control zebrafish, p = 0.38; erythroblasts 27 ± 3% compared to 18 ± 6% in control zebrafish, p = 0.08; 
monocytes 17 ± 7% compared to 22 ± 3% in control zebrafish, p = 0.32. # 26 = lymphocytes 9 ± 4% 
compared to 27 ± 12% in control zebrafish, p =0.33; myelocytes 50 ± 2 % compared to 33 ± 15% in 
control zebrafish, p = 0.12; erythroblasts was 10 ± 1% compared to 18 ± 6% in control zebrafish, p = 
0.09; monocytes 22 ± 2% compared to 22 ± 3% in control zebrafish, p = 1, Figure 10). 
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Figure 10. Blood cell count rating of kidney imprints of 9 months aged CREB-overexpressing and control zebrafish. 
A) percentage of the diverse hematopoietic lineage cells. B) Histogram representation of the hematopoietic lineages. Bars 
represents the mean of 3 independent measurement for each sample. * means statistical significance = p < 0.05. 
Representative pictures of Wright-Giemsa staining of 9 months aged zebrafish kidney imprints. C) pu.1:eGFP control 
zebrafish showed normal rate of lymphocytes, myelocytes, erythroblasts and monocytes. D and E) pu.1:eGFP_CREB # 21 
and pu.1:eGFP_CREB # 24 showed an unbalanced blood cell count with higher monocytes number. Legend: white arrow: 
lymphocytes; green arrow: myelocytes; red arrow: erythroblasts; yellow arrow: monocytes. 60x original magnification. 
 
CREB induces myeloproliferative neoplasms in zebrafish 
9 months post CREB injection we observed atypical zebrafish phenotypes and behaviour. From 9 to 
14 months, ten CREB-injected zebrafish with abnormal phenotype presented an evident 
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abdominal/dorsal mass. In particular, 4 zebrafish were found dead, and 6 zebrafish were sacrificed 
because they presented a sick phenotype (Figure 11).  
 
 
Figure 11. Abnormal phenotypes developed in pu.1:eGFP_CREB zebrafish after a latency period. A) pu.1:eGFP 
injected zebrafish showed a normal phenotype. B) pu.1:eGFP_CREB injected zebrafish showed atypical phenotypes with 
abdominal or dorsal prominence.  
 
To investigate about the nature of the observed mass, we sectioned the paraffine-embedded zebrafish. 
Whole fish histological sagittal sections stained with H&E revealed an evident abdominal mass 
composed by clonal cells, with open chromatin texture (Figure 12 A, B). In particular, we noted 
infiltrations of clonal myeloid cells presenting the same morphology of the mass in gills, muscles and 
adipose tissue (Figure 12F-L).  
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Figure 12. H&E histochemical staining of paraffined sections of pu.1:eGFP and pu.1:eGFP_CREB. A) H&E staining 
of a sagittal section of 1 year aged pu.1:eGFP injected zebrafish. Regular organs and tissues were evident. B) H&E staining 
of a sagittal section of 1 year aged pu.1:eGFP_CREB injected zebrafish revealed a prominent mass that filled the abdominal 
cavity. C) 10x and higher 60 x original magnification of the mass found in CREB-overexpressing zebrafish showed clonal 
cells with open chromatin texture. The presence of cells throughout gills, muscles and adipose tissues. D) higher 
magnification of kidney of the control fish showed a normal tubular structure, with hematopoietic cells within the proper 
kidney tissue. E) higher magnification of kidney of the CREB-overexpressing fish revealed a disorganized structure, with the 
presence of blobs containing clonal cells with open chromatin texture. F) 20x original magnification of gills of the control 
fish showed a regular shape. G) 20x original magnification of gills of the CREB-overexpressing zebrafish revealed a 
disrupted gills shape, with infiltration of invading cells. H) muscles of control fish showed normal fibers, with no cells 
between fibers. I) adipose tissue of control zebrafish presenting a regular morphology without cells infiltration within adipose 
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cells. L) muscle and adipose tissue of CREB-overexpressing zebrafish revealed high infiltration degree of invading cells, 
which colonized muscle fibers and interstice within adipose cells. High magnification showed the same cell type as those 
found in the abdominal mass (C). 
 
We found that the clonal abnormal infiltrating cells of the abdominal mass were derived from myeloid 
eGFP-CREB expressing cells by immunohistochemical assay for CREB and for GFP, that were 
expressed throughout the mass. Moreover, we revealed that these cells were highly proliferating 
because of strong positivity of the PCNA antibody (Figure 13).  
 
 
Figure 13. Characterization of abdominal mass cells by IHC. A) IHC for CREB showed a strong positivity of infiltrating 
cells, opposite of vessel forming erythrocytes, which were negative stained (yellow arrow). B) IHC for GFP showed a high 
positivity of mass cells. C) IHC for PCNA revealed a broad positive signal throughout the mass. 60 x original magnification. 
 
To further investigate the nature of these aberrant cells, mass cell sorting has been performed. Based 
on forward scattering (FSC) and side scattering (SSC) physical parameters, the mass forming cells 
were localized in the mono-myeloid compartment. Cytospin of these cells was done, and by Wright-
Giemsa staining we proved that the totality of cells were monocytes. Moreover, most of sorted cells 
were in proliferation, as pointed out by chromatin condensation in the nucleus or by the presence of 
just divided cells (data not shown).  
To confirm that mass forming cells were monocytes, and to explore if the kidney marrow of sick 
CREB-overexpressing zebrafish may have a role in the origin of the mass, we performed a series of 
imprints of abdominal mass and kidney of sick zebrafish and stained them with Wright-Giemsa. By 
microscope we verified that both, the mass and the kidney cells, had monocytic features, with 
basophilic cytoplasm and eccentric nucleus. Kidney marrow was completely populated by monocytes, 
to the detriment of other hematopoietic lineages. To examine the magnitude of this imbalance, blood 
cell counts of the imprints from kidney and mass of sick CREB-overexpressing zebrafish and controls 
were executed. As illustrated in figure 14, kidney and mass of pu.1:eGFP_CREB zebrafish showed no 
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variation in lymphocytes number (31 ± 4% and 32 ± 8% compared to 30 ± 2% in control zebrafish, p = 
0.76 and p = 0.70, respectively) and a high significant impairment of myelocytes (1 ± 1% and 3 ± 1% 
compared to 26 ± 1% in control zebrafish, both p < 0.01). Erytroblasts showed to be increased in sick 
kidney, whereas decreased in the mass (38 ± 4% in kidney of CREB-overexpressing zebrafish, and 6 ± 
6% in abdominal mass compared to 26 ± 1% in control zebrafish, p = 0.05 and p = 0.01 respectively). 
Monocytes revealed a huge increase, confirming to be almost the unique cell type in the abdominal 
mass (32 ± 6% in kidney of CREB-overexpressing zebrafish, and 60 ± 14% in abdominal mass 
compared to 19 ±1 % in control zebrafish, p = 0.10 and p < 0.01, respectively).  
 
 
 
Figure 14. Blood cell count of kidney imprints of 1 year aged sick CREB-overexpressing or control zebrafish and 
representative pictures of Wright-Giemsa staining of 1 year aged zebrafish kidney imprints. A) Table of percentage of 
the diverse hematopoietic lineage cell number (n = 3). B) Histogram representation of the different hematopoietic lineages. 
Bars represents the mean of 3 independent measurement for each sample. * means statistical significance = p < 0.05. C) 
pu.1:eGFP control zebrafish with normal rate of lymphocytes, myelocytes, erythroblasts and monocytes. D and E) kidney and 
mass of sick pu.1:eGFP_CREB showed disrupted hematopoietic lineage balance, with a predominance of monocytes at the 
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expense of myeloid cells. CREB-overexpressing kidney imprint showed cells in mitosis phase (green arrowhead). Legend: 
white arrow: lymphocytes; green arrow: myelocytes; red arrow: erythroblasts; yellow arrow: monocytes. 60x original 
magnification. 
 
We further characterized that the mass infiltration was composed principally of monocytes for their 
high activity of alpha-naphthyl acetate esterase (ANAE) as shown in Figure 15. 
 
 
Figure 15. ANAE assay on imprints of control zebrafih kidney and CREB zebrafish mass. A) ANAE staining was 
positive in few cells (monocytes) due to heterogeneity of the normal kidney marrow. B) ANAE staining on mass imprint 
showed strong positive activity into cytoplasm of the most of cells, being monocytes. 60 x original magnification. 
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DISCUSSION 
CREB has been found to be overexpressed in pediatric and adult acute myeloid leukemia. It 
played a role in abnormal cell proliferation, cell cycle progression and conferred high clonogenic 
potential in vitro and in vivo. Since it was established to be a proto-oncogene in AML, the molecular 
pathway of transformation has not been identified yet [6, 7]. 
Here, the enforced CREB overexpression in myeloid lineage of zebrafish embryos provided 
evidence that it enhanced an aberrant myelopoiesis since 20 hpf, leading to a myeloproliferative 
disease in the adult zebrafish. Therefore we revealed that CREB overexpression mediates a myeloid 
disease in zebrafish model, as previously described in human cell lines and mice [6, 7]. 
Zebrafish Creb1 shared 88.7% identity with human CREB gene, including the functional 
domains [15]. We demonstrated, that CREB worked as a transcription factor in zebrafish myeloid cells 
increasing expression of genes leading to the perturbation of primitive hematopoiesis. The analysis of 
CREB target genes expression, that were previously found to be aberrantly induced upon CREB 
higher expression in human bone marrow cells [22], revealed that there was a trend towards 
upregulation of genes that positively control proliferation, in contrast to a down-regulation of genes 
that inhibit cell cycle progression. Ccna1 expression, which controls advance in cell cycle and is 
already known to be expressed in several leukemic cell lines, as well as ccnd1 expression, which 
normally regulates cell cycle G1/S transition and whose overexpression was observed in a variety of 
tumors, were found more expressed in CREB-injected zebrafish. On the contrary, p21, which normally 
encodes a cyclin-dependent kinase inhibitor protein functioning as a negative regulator of cell cycle 
progression at G1 advance signals [25], was found decreased in CREB-overexpressing zebrafish. 
Other genes involved in leukemia, such as stat3, gata2 and bcl-2 were found upregulated by CREB 
overexpression. Despite this perturbation of gene expression, zebrafish at larvae stage did not show 
aberrant phenotypes. Then, when we monitored the effects of prolonged CREB overexpression in 
myeloid lineage, we revealed that from 6 months after CREB plasmid injection, the kidney marrow of 
adult zebrafish had increased the myeloid and monocytic compartment, at the expense of the lymphoid 
one. This finding was in agreement with previous studies in vitro and in vivo, where enforced CREB 
expression promoted an increased myeloid cell proliferation and survival in vitro, as well as an 
aberrant myelopoiesis in both the bone marrow and spleen of transgenic mice that recapitulated a 
myeloproliferative disease after 1 year [6].  
Starting from 9 months after injection, CREB-overexpressing zebrafish developed a sick 
phenotype, with an evident abdominal and dorsal swelling. The animals died with a latency period that 
was variable from 9 to 15 months, suggesting that further events may occur to take to disease. The 
analysis of sick animals revealed the presence of a mass composed by clonal cells, with large nucleus 
and open chromatin texture characters that resemble cancer cells. These features caused infiltration of 
mass-like cells throughout the zebrafish tissues and organs that ultimately led to fish death. By 
morphological analysis, we found that tumor cells expressed eGFP_CREB and therefore derived from 
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the kidney marrow. They acquired the ability to rapidly expand due to they high proliferation rate and 
to migrate. The paired mass and kidney showed to have the same cell morphology, such as a complete 
absence of myelocytes opposed to an overt preponderance of monocytes, disclosing a severe disrupted 
myelopoiesis.  
Nevertheless, these results supported that CREB overexpression in myeloid compartment 
might be considered a driving force of cell cycle dysregulation and proliferation advantages, that when 
subjected to additional hits is able to induce myeloid transformation. Here, we described one single 
adult CREB-injected zebrafish developing an acute lymphoblastic leukemia (ALL), characterized by a 
total lymphocytes invasion of the kidney marrow. In fact, pu.1 promoter has been used to drive 
expression specifically in early myeloid cells [13, 14, 16, 26], it also plays a pivotal role in the 
differentiation of lymphoid cells, and it has been found expressed in most of the hematopoietic cells 
including B lymphocytes, macrophages, neutrophils, mast cells, early erythroid and megakaryocytes 
[27, 28]. Of relevance, CREB was found to be overexpressed in both adult and pediatric ALL as well 
[6, 7]. This result, supported our hypothesis that CREB is a proto-oncogene, and additional events and 
the time of occurrence may have a crucial role in causing different cell transformation. 
Finally, we recapitulated a multistep model for CREB-associated myeloid disorders, where 
CREB overexpression triggered proliferation advantages and gene expression alteration that conferred 
pre-oncogenic features to clones that in turn, by accumulating mutations and/or epigenetic changes, 
took to hematologic disease. This is the first evidence that a zebrafish model may constitute a valid 
model to test the role of CREB in leukemogenesis as well as the possibility to test new therapeutic 
molecules associated to hematopoietic/leukemic disease. The further identification of CREB 
overexpression driven pathways may unravel the leukemic process, and identified new targets that, 
together with new compounds directed to block CREB-transcriptional activation [29, 30], would open 
for novel therapeutic opportunities. 
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CHAPTER 5 
_______________________ 
 
CONCLUSIONS 
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During my PhD, we definitively ascertained that CREB was a proto-oncogene, and for this 
reason we considered the possibility that targeting its expression might have great relevance in 
leukemia therapy.  
We firstly verified the effects that CREB levels reduction might have on leukemia cell 
proliferation and disease progression. The first hypothesis that we formulated was that ICER, the 
endogenous CREB competitor able to recognize CRE sequences and stop its transcriptional activity, 
was maintained at low levels in AML. This led to CREB overexpression and to the aberrant activation 
of its targets in order to sustain leukemia. So, we restored ICER expression in leukemic cell lines and 
in AML primary cultures, and verified that CREB protein levels decreased together with its target 
genes expression. We then considered identifying the mechanism that was activated by this 
modification. We unveiled that ICER restoration had the main effect on two particular target genes: 
the dual-specificity phosphatases, DUSP1 and DUSP4. DUSP1 and DUSP4, directly repressed by 
ICER, activated the p38 apoptotic mediated pathway, which in turn, triggered caspase-dependent 
apoptosis. Being ICER restoration involved in leukemia cell death, we considered testing its role in 
drug sensitivity, and we revealed that when ICER was restored, it enhanced the chemotherapeutic 
response. Finally, we revealed that ICER downregulation in AML had a crucial role in sustaining 
leukemia proliferation, and that ICER may be considered a tumor-supressor to be further validated. 
We also identified that ICER restoration mediated chemotherapy anticancer activity and drove 
leukemia cell program from survival to apoptosis. It is reasonable that the strategy to target CREB 
overexpression through ICER may improve conventional chemotherapy and inhibit leukemia 
progression.  
Next, we aimed to understand the cause of CREB overexpression in AML. It was previously 
shown that CREB overexpression was dependent on miR-34b, a micro RNA which physiologically 
targets the 3’UTR of CREB gene. We revealed that miR-34b expression was maintained low in AML 
to support CREB overexpression. We dissected that miR-34b promoter was hypermethylated in AML 
cell lines, causing miR-34b downregulation and in turn CREB overexpression, as well as in patients 
diagnosed with AML. Then, we found that miR-34b was upregulated (since it was not 
hypermethylated at its promoter) in pediatric patients affected by preleukemic hematopoietic disease 
as juvenile myelomonocytic leukemia (JMML) and myelodysplastic syndrome (MDS) with the 
concomitant low CREB expression. In paired samples of myelodysplastic syndromes and subsequent 
acute myeloid leukemia from the same patients, we confirmed miR-34b promoter hypermethylation at 
leukemia onset, with a strong CREB target genes dataset differentially expressed between the two 
disease stages. This subset of CREB targets was confirmed to associate with high risk myelodysplastic 
syndrome. These results confirmed that miR-34b played a crucial role on CREB expression 
controlling myeloid transformation. To support this hypothesis we evaluated miR-34b tumor 
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suppressor potential in vitro and in vivo, finding that miR-34b restoration decreased AML engraftment 
and progression. Finally, we point out the possibility of evaluating the miR-34b as a therapeutic agent 
to be tested in an in vivo model,. This is supported by recent experimental evidences which 
demonstrated that correction of specific miRNA alterations using miRNA mimics or antagomirs, 
vehiculated both as short double stranded oligonucleotides or in form of viral vectors, can normalize 
the gene regulatory network and signaling pathways, and reverse the phenotype in cancerous cells. 
Thus miRNA-based gene therapy provides an attractive anti-leukemic approach.  
The identification of miR-34b tumor suppressor ability, and the discovery of a dataset of CREB target 
genes representing a novel transcriptional network that may control myeloid transformation, drove us 
to look at an ideal in vivo model to better interpret our findings. We considered the zebrafish model for 
its numerous advantages that led to its widespread use in both developmental studies and cancer 
research, such as high regenerative ability, rapid and transparent embryonic development, and easy 
genetic manipulation. To mimic the condition found in AML patients, we integrated a plasmid coding 
human CREB under pu.1 promoter into fertilized egg at one cell stage to overexpress CREB in the 
myeloid lineage. Up to now, this is the first time that a CREB-overexpressing zebrafish model was 
performed. Moreover, zebrafish overexpressing CREB resembled the same dysmyelopoiesis already 
seen in vitro and in CREB transgenic mice, with a relevant perturbed CREB target gene expression. 
CREB-overexpressing zebrafish recapitulated myeloproliferative disease after one year, with more 
features of a leukemia than previously seen in mice. Finally, we consider that this model represents the 
best way to evaluate the main effects of CREB overexpression on its downstream effectors in vivo, 
with the aim to unravel the leukemogenic mechanism. 
Due to the availability of a variety of fluorescent transgenic reporter lines and the easy genetic 
manipulations, we intend to test ICER and miR-34b as targets to reduce CREB expression. Moreover, 
because of new therapeutic compounds directed to CREB-transcriptional activity arrest has been 
created, we aim to test them alone and in combination with conventional chemotherapy in this 
zebrafish model. 
Finally, during my PhD, I confirmed CREB to play a crucial role in supporting AML. I set up 
an in vivo model that recapitulates myeloid disease and thus represents a valid approach to delineate 
the mechanism of leukemia induction, as well as an interesting model where the additional events that 
probably follow CREB overexpression will be further addressed. Moreover, the zebrafish model will 
be useful to test the efficacy of new molecules that target CREB, with the perspective to hit this 
transcription factor. In fact it was demonstrated to have a broad role in many cellular processes, and its 
aberrant regulation is increasingly found to be involved in many cancer types, suggesting that there 
might be an underpinning CREB-regulated common pathway that urgently need to be identified. I 
believe that by targeting CREB, we can contribute to support and improve AML therapy.  
